<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Clinical practice guideline on the comprehensive care of people with Alzheimer's disease and other dementias.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Development Group of the Clinical Practice Guideline [trunc]. Clinical practice guideline on the comprehensive care of people with Alzheimer's &#xD;&#xA;disease and other dementias. Barcelona (Spain): Agency for Health Quality and Assessment of Catalonia (AQuAS); 2010. 499 p.  [688 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Alzheimer's disease  (331.0); Behavior therapy  (94.33); Dementia in conditions classified elsewhere without behavioral disturbance  (294.10); Dementia with lewy bodies  (331.82); Electroencephalogram  (89.14); General physical examination  (89.7); Neurologic examination  (89.13)"/><FieldValue Value="MSH: Advance Directives ; AIDS Serodiagnosis ; Alzheimer Disease ; Antipsychotic Agents ; Behavior Therapy ; Biopsy ; Blood Cell Count ; Cholinesterase Inhibitors ; Cognitive Therapy ; Comprehensive Health Care ; Dementia ; Dementia, Vascular ; Diagnostic and Statistical Manual of Mental Disorders ; Domperidone ; Electroencephalography ; Frontotemporal Dementia ; Frontotemporal Lobar Degeneration ; Galantamine ; Genetic Counseling ; Genetic Testing ; Hygiene ; Indans ; Inservice Training ; International Classification of Diseases ; Levodopa ; Lewy Body Disease ; Magnetic Resonance Imaging ; Memantine ; Mental Competency ; Motor Activity ; Neurologic Examination ; Neuropsychological Tests ; Palliative Care ; Patient Care Team ; Phenylcarbamates ; Physical Examination ; Piperidines ; Positron-Emission Tomography ; Primary Health Care ; Psychiatric Status Rating Scales ; Psychotherapy ; Questionnaires ; Research ; Restraint, Physical ; Self-Help Groups ; Serotonin Uptake Inhibitors ; Social Support ; Symptom Assessment ; Syphilis Serodiagnosis ; Terminal Care ; Therapy, Computer-Assisted ; Tomography Scanners, X-Ray Computed ; Tomography, Emission-Computed, Single-Photon ; Tomography, X-Ray Computed ; Trazodone ; Urination "/><FieldValue Value="MTH: Abuse prevention ; Acetylcholinesterase Inhibitors ; AIDS Serodiagnosis measurement ; Alzheimer's Disease ; Biopsy ; blood cell count ; Blood folate measurement ; Calcium measurement ; Caregiver support (regime/therapy) ; Cholinesterase Inhibitors ; Cognitive Therapy ; Computed Tomography Scanning Systems ; Dementia ; Domperidone ; Electroencephalography ; Emotional support ; Frontotemporal dementia ; Frontotemporal Lobar Degeneration ; Genetic Counseling ; Genetic screening method ; Glucose measurement ; Hygiene ; Inservice Training ; International Classification of Diseases ; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) ; Lewy Body Disease ; Magnetic Resonance Imaging ; Mini-mental state examination ; Neurologic Examination ; Palliative Care ; Physical activity ; physical examination ; Physical Restraint (procedure) ; Positron-Emission Tomography ; Primary Health Care ; Psychotherapy ; Questionnaires ; research ; Selective Serotonin Reuptake Inhibitors ; Serotonin Uptake Inhibitors ; Social support ; Support Groups ; Tau Protein Measurement ; terminal patient care ; Thyroid stimulating hormone measurement ; Tomography, Emission-Computed, Single-Photon ; Treponema pallidum antibody measurement ; Urination ; VITAMIN B12 MEASUREMENT ; X-Ray Computed Tomography "/><FieldValue Value="PDQ: biopsies ; computed tomography ; domperidone ; levodopa ; magnetic resonance imaging ; tomography, emission computed, single photon "/><FieldValue Value="SNOMEDCT_US: Abuse prevention  (370882000); Alzheimer's disease  (26929004); Anti-psychotic agent  (10784006); Anti-psychotic agent  (372482001); Anticholinesterase drug  (372765004); Anticholinesterase drug  (52761007); Behavioral therapy  (166001); Biopsy  (129314006); Biopsy  (86273004); Biopsy of brain tissue  (230842002); Blood cell count  (88308000); Calcium measurement  (71878006); Caregiver support  (386229000); Caregiver wellbeing status  (405193005); Cerebrospinal fluid examination  (167699000); Cerebrospinal fluid Tau protein measurement  (412923001); Cognitive therapy  (183383008); Cognitive therapy  (228553007); Cognitive therapy  (228557008); Cognitive therapy  (304891004); Computerized axial tomography  (77477000); Dementia  (52448006); Dementia associated with Parkinson's Disease  (425390006); Dementia management  (386257007); Domperidone  (32955006); Domperidone  (387181004); Donepezil  (108497001); Donepezil  (386855006); Dying care  (182964004); Dying care  (385736008); Electroencephalogram  (54550000); Electrolytes measurement  (79301008); Emotional support  (133921002); Frontotemporal dementia  (230270009); Galantamine  (323377002); Galantamine  (395727007); Genetic counseling  (79841006); Genetic test  (405824009); Glucose measurement  (36048009); Levodopa  (15383004); Levodopa  (387086006); Magnetic resonance imaging  (113091000); Magnetic resonance imaging  (312250003); Magnetic resonance imaging unit  (90003000); Memantine  (406457005); Memantine  (406458000); Micturition  (28278009); Mini-mental state examination  (273617000); Neurological assessment  (225398001); Neurological assessment  (84728005); Neuropsychological testing  (307808008); Palliative care  (103735009); Phenylcarbamate  (429302000); Physical activity  (48761009); Physical activity  (68130003); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Physical restraint  (386423001); Positron emission tomography  (363678002); Positron emission tomography  (82918005); Positron emission tomography unit  (39821008); Positron emission tomography unit  (462323006); Psychologic cognitive testing and assessment  (4719001); Psychotherapy  (75516001); Rivastigmine  (323368009); Rivastigmine  (395868008); Selective serotonin re-uptake inhibitor  (349854005); Selective serotonin re-uptake inhibitor  (373225007); Senile dementia of the Lewy body type  (312991009); Senile dementia of the Lewy body type  (80098002); Single photon emission computerized tomography  (105371005); Single photon emission computerized tomography  (260222006); Support groups  (224879000); Syphilis infectious titer test  (269828009); Syphilis infectious titer test  (40675008); Thyroid stimulating hormone measurement  (61167004); Trazodone  (372829000); Trazodone  (7336002); Vascular dementia  (429998004); Vitamin B12 measurement  (14598005)"/><FieldValue Value="SPN: SYSTEM, NUCLEAR MAGNETIC RESONANCE IMAGING ; SYSTEM, TOMOGRAPHY, COMPUTED, EMISSION ; SYSTEM, X-RAY, TOMOGRAPHY, COMPUTED "/><FieldValue Value="UMD: Physiologic Monitor Modules, Electroencephalography  (20-783); Procedure Kit/Trays, Biopsy  (10-401); Scanning Systems, Computed Tomography  (13-469); Scanning Systems, Gamma Camera, Single Photon Emission Tomography  (18-444); Scanning Systems, Magnetic Resonance Imaging  (16-260); Scanning Systems, Positron Emission Tomography  (16-375)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Alzheimer's disease (AD) and other dementias, including vascular dementia (VD), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB) and frontotemporal lobar degeneration (FTLD)&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: The clinical practice guideline (CPG) does NOT include:&lt;/p&gt;&#xD;&#xA;&lt;ul class=&quot;contentListFont&quot;&gt;&#xD;&#xA;    &lt;li&gt;Dementias secondary to vitamin B&lt;sub&gt;12&lt;/sub&gt; deficiency and normotensive hydrocephalus &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dementia associated with infectious diseases: human immunodeficiency virus (HIV), viral or bacterial infections &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dementias due to human spongiform encephalopathies (prionopathies) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Screening" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Geriatrics" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Neurology" /><FieldValue Value="Pharmacology" /><FieldValue Value="Physical Medicine and Rehabilitation" /><FieldValue Value="Psychiatry" /><FieldValue Value="Psychology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Allied Health Personnel" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Nurses" /><FieldValue Value="Occupational Therapists" /><FieldValue Value="Other" /><FieldValue Value="Patients" /><FieldValue Value="Pharmacists" /><FieldValue Value="Physical Therapists" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Psychologists/Non-physician Behavioral Health Clinicians" /><FieldValue Value="Social Workers" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Main Objective&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;To prepare an evidence-based clinical practice guideline (CPG) on the comprehensive care of people with Alzheimer's disease (AD) and other dementias, with national scope that offers &quot;systematically developed recommendations to help professionals and patients take decisions about the most appropriate healthcare, and select the most adequate diagnostic or therapeutic options to address a specific clinical condition or health problem&quot;, integrating and coordinating the different Spanish National Health Services (SNHS) health devices involved&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Secondary Objectives&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To guarantee equity in health and social care of people affected by dementia and their families, regardless of their age, sex, social status, education or culture &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To reduce the variability of clinical practice in comprehensive care of dementias, both regarding its diagnostic aspects and its therapeutic management &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To offer comprehensive and integral care to the people, relatives and their environment, with a multi-interdisciplinary vision, evaluating biological, psychological and social aspects (bio-psychosocial approach) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To improve the clinical skills of the health and social professionals involved in the care of people with dementia and their relatives &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To use the most up-to-date diagnosis and treatment options based on the best scientific evidence and on the consensus of experts &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To assess the effectiveness, safety and efficacy of the different diagnosis techniques and of the pharmacological (specific and symptomatic) and non-pharmacological therapeutic proposals &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To provide useful information to the population, people affected by mild cognitive impairment or dementia, relatives of the people affected, caregivers, health and social services professionals, and other professionals related to any of the aspects involved in the care of dementia, to facilitate decision-making &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To develop quality healthcare indicators that permit assessing the implementation of the recommendations established in the CPG &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To establish recommendations to increase the knowledge of all the professionals involved at undergraduate, post-graduate and lifelong training level &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To prepare general and specific information material for people affected by dementia and above all for their relatives and caregivers, which will give them a better idea of the dementia process as a whole and each one of the elements that affects the course of the disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To establish recommendations for the participation and development of research in dementias, from the different healthcare levels, in collaboration with the University, and the institutes and organisations dedicated to research &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;People affected by dementia, whatever the age of onset of the process, and their relatives and caregivers&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Prevention/Diagnosis/Evaluation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Prevention of conversion of mild cognitive impairment to dementia (no recommendation made) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Primary prevention of dementia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Genetic analysis to identify pathogenic mutations and genetic counselling &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Obtaining data from a reliable informant &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of symptoms &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Physical and neurological exam &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of established diagnostic criteria to diagnose dementia (e.g., Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision [DSM-IV-TR] and International Classification of Diseases and Related Health Problems, 10th edition [ICD-10] clinical criteria) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Neuropsychological testing, questionnaires, screening tests for cognitive impairment (e.g., Mini Mental State Examination [MMSE]) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Laboratory tests including haemogram, thyroid-stimulating hormone (TSH), electrolytes, calcium and glucose, folate, vitamin B&lt;sub&gt;12&lt;/sub&gt;, syphilis and human immunodeficiency virus (HIV) serologies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Apolipoprotein E (APOE) genotype testing (not recommended) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Analysis of T-tau, A&amp;beta;-42 and P-tau in cerebrospinal fluid (CSF) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;CSF 14-3-3 protein test in diagnosis of Creutzfeldt-Jakob Disease (CJD) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Computed tomography (CT) and magnetic resonance imaging (MRI) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Single-photon emission computed tomography (SPECT) and positron emission tomography (PET) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Electroencephalogram (EEG) in diagnosis of CJD &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cerebral biopsy only in highly selected cases &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Population-based screening (not recommended) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment/Management&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Role of primary care team in dementia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Criteria for referring to specialist dementia care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of multidisciplinary team in dementia care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Role of the social-health network in dementia care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Informing patients and families of the dementia diagnosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pharmacological treatment of dementia&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Acetylcholinesterase (ACE) inhibitors (donepezil, rivastigmine, galantamine) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Memantine &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Levodopa in dementia with Lewy bodies &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Selective serotonin reuptake inhibitors (SSRIs) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Trazodone &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Atypical neuroleptics &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Domperidone to treat gastrointestinal side effects of ACE inhibitors &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Non-pharmacological treatment of dementia&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Cognitive intervention programmes, including computer based &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Long-term physical activity programmes &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Behavioural changes, programmed hygiene, and induced urination &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of behavioural and psychological symptoms of dementia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recognizing and managing adverse effects of treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of response to treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of caregiver burden &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Interventions to prevent caregiver burden (e.g., mutual aid groups, therapeutic aid groups, emotional support groups, psychotherapy) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of early onset dementia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ethical and legal aspects in the management of dementia (e.g., detecting and preventing abuse, advance directives, evaluation of competences, mechanical restraints) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Palliative care (PC) and end-of-life issues &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diffusion, training, and research into care of people with dementia &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: The following therapies were considered but not recommended for dementia treatment: hormone therapy; nonsteroidal anti-inflammatory drugs (NSAIDs); piracetam; propentofylline; nimodipine; selegiline; ibedenone; dihydroergotoxine mesylate; citicoline or cytidine diphosphate-choline (CDP-choline); vitamins E, B&lt;sub&gt;1&lt;/sub&gt;, B&lt;sub&gt;6&lt;/sub&gt;, B&lt;sub&gt;12&lt;/sub&gt;, folic acid, and copper supplements; gingko biloba; lecithin; alpha-lipoic acid; omega-3 fatty acids; ginseng; yokukansan (TJ-54); therapeutic touch massage.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Signs and symptoms of dementia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sensitivity and specificity of diagnostic/assessment criteria &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Efficacy of medications and behavioral interventions &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Maintenance of functional abilities &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quality of life &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Bibliographic search in: PubMed/Medline, The Cochrane Library, PsycINFO, Scopus, Tripdatabase, CMA Infobase (Canada), CPG Gu&amp;iacute;aSalud Library of the SNS, International Guidelines Library (GIN), National Electronic Library for Health and U.S. National Guideline Clearinghouse.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Timeline: From January 2006 to February 2009.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Languages: Spanish, Catalan, French, English and Italian.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The first phase involved a preliminary search for clinical practice guidelines (CPGs) and systematic reviews in the aforementioned databases. CPGs were identified and evaluated using the Appraisal of Guidelines for Research and Evaluation (AGREE) instrument, after which it was decided whether to include them as a secondary source of evidence, apart from serving as an inspiration and example for some of the sections of this guideline, due to their rigour and clarity. This was carried out in agreement with the preparation-adaptation-updating methodology used in the CPG on asthma of the Basque Country. Parts from these CPGs, consensus documents and position papers (recommendations) of scientific societies have been considered (see Appendix 6 in the original guideline document). A second phase entailed an extended search for original studies (randomised control trial [RCT]; cohort studies, case and control studies, etc.) until July 2009. Later, search alerts were created in PubMed to identify relevant studies in high impact biomedical journals, and the entire development group was consulted until May 2010, when the first draft of the guideline was closed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Scottish Intercollegiate Guidelines Network (SIGN) &lt;strong&gt;Levels of Evidence&lt;/strong&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Levels of Evidence: Scottish Intercollegiate Guidelines Network (SIGN)&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th width=&quot;5%&quot; class=&quot;Center&quot; valign=&quot;top&quot;&gt;1++&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High quality meta-analyses, systematic reviews of clinical trials or high-quality clinical trials with very little risk of bias.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1+&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well-conducted meta-analyses, systematic reviews of clinical trials, or well-conducted clinical trials with low risk of bias.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1-&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Meta-analyses, systematic reviews of clinical trials or clinical trials with high risk of bias.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2++&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High-quality systematic reviews of case-control or cohort studies. Cohort or case-control studies with very low risk of bias and with high probability of establishing a causal relationship.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2+&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well-conducted case-control or cohort studies with low risk of bias and a moderate probability of establishing a causal relationship.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2-&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case-control or cohort studies with a high risk of bias and a significant risk that the relationship is not causal.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Non-analytical studies such as case reports and case series.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;4&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert opinion.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Studies classified as 1- and 2- should not be used in the process of developing recommendations due to their high potential for bias.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review with Evidence Tables" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The methodology used in this guideline is contained in detail in the &quot;Methodology manual for the preparation of clinical practice guidelines in the Spanish National Health System&quot; (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Assessment of the quality of the studies and summary of evidence for each question followed the methodology of Scottish Intercollegiate Guidelines Network (SIGN) recommendations.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Formulation of the Clinical Practice Guideline (CPG) Development Group&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The group is comprised of health professionals, specialists in neurology, geriatrics, psychiatry, family medicine, neuropsychology, psychology, nursing, pharmacy, psychogeriatrics, preventive medicine and public health, forensic medicine and social work, and non-health professionals (lawyers and economists) involved in the study and treatment of dementia. Some of them have experience in the legal and bioethics area, are linked to the Social and Health Steering Plan of the Catalan Department de Salut (DS) or are specialised in methodology from the Ag&amp;egrave;ncia d'Informaci&amp;oacute;, Avaluaci&amp;oacute; i Qualitat en Salut (AIAQS). The development group has been guided by a coordination team. To incorporate the perspective of relatives, representatives from associations of relatives and patients have participated in the development group and in the external view of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Formulation of Recommendations Based on the &quot;Formal Assessment&quot; or &quot;Reasoned Judgement&quot; of the Scottish Intercollegiate Guidelines Network (SIGN)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The classification of the evidence and grading of the recommendations have been carried out using the SIGN system. The Oxford Centre for Evidence-Based Medicine system has been used for the diagnosis questions as suggested by the CPG preparation manual of the Spanish National Health System for diagnostic test studies (see the &quot;Rating Scheme for the Strength of the Recommendations&quot; field and the &quot;Availability of Companion Documents&quot; field). Controversial recommendations or those where there was a lack of evidence have been solved by simple consensus of the development group.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;strong&gt;Scottish Intercollegiate Guidelines Network (SIGN) &lt;/strong&gt;Grades of Recommendation for Intervention Studies&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Grades of Recommendation for Intervention Studies: Scottish Intercollegiate Guidelines Network (SIGN)&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least one meta-analysis, systematic review or clinical trial rated as 1++ and directly applicable to the target population of the guideline, or body of scientific evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A body of scientific evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 1++ or 1 +.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A body of scientific evidence consisting of studies rated as 2+, directly applicable to the target population of the guideline and overall consistency of results; or evidence extrapolated from studies classified as 2++.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Scientific evidence level 3 or 4, or extrapolated evidence from studies rated as 2 +.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Good Clinical Practice (GCP)*&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommended practice based on clinical experience and the consensus of the editorial team.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*At times, the development group realised that there were some important practical aspects that they wished to stress but for which there was probably no scientific evidence to support them. In general these cases have to do with some aspects of the treatment considered as good clinical practice and that nobody would normally question. These aspects are evaluated as good practice points. These messages are not an alternative to the scientific evidence-based recommendations, but rather, they must only be considered when there is no other way to highlight this aspect.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grades of Recommendation for Diagnostic Studies&amp;dagger;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; Level of evidence Ia or Ib studies [in the guideline it appears as 2++]&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; Level of evidence II studies [in the guideline it appears as 2+]&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; Level of evidence III studies [in the guideline it appears as 2-]&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; Level of evidence IV studies [in the guideline it appears as 3 or 4]&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&amp;dagger;Adapted from The Oxford Centre for Evidence-based Medicine Levels of Evidence&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline developers reviewed published cost analyses.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;External reviewers have participated in the review of the second draft. The different scientific societies involved have been contacted (Sociedad Espa&amp;ntilde;ola de Neurolog&amp;iacute;a, Societat Catalana de Neuropsicologia, Societat Catalana de Medicina Familiar i Comunit&amp;agrave;ria, Societat Catalana de Infermeria en Salut Mental, Sociedad Espa&amp;ntilde;ola de Psicogeriatr&amp;iacute;a, Sociedad Espa&amp;ntilde;ola de Medicina Familiar y Comunitaria and Sociedad Espa&amp;ntilde;ola de Geriatr&amp;iacute;a y Gerontolog&amp;iacute;a).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Levels of evidence (&lt;strong&gt;1++&lt;/strong&gt; to &lt;strong&gt;4&lt;/strong&gt;) and grades of recommendation (&lt;strong&gt;A&lt;/strong&gt; to &lt;strong&gt;D&lt;/strong&gt; and &lt;strong&gt;Good clinical practice&lt;/strong&gt;) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definition and Classification of Dementias&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Are the Risk Markers of Conversion of Mild Cognitive Impairment (MCI) to Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Different biological and neuroimaging markers can be used to help predict the progression of MCI to dementia in a research context, but they cannot be recommended for use yet in normal clinical practice.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Is There Any Treatment That Modifies the Progression of MCI?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - The use of acetylcholinesterase (ACE) inhibitors to avoid or delay the progression of MCI to dementia is not currently recommended.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - The use of nonsteroidal anti-inflammatory drugs (NSAID), replacement therapy with oestrogens, ginkgo biloba or vitamin E to avoid or delay the progression of MCI to dementia is not currently recommended.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - There is not enough evidence to recommend cognitive stimulation or physical exercise to avoid or delay the progression of MCI to dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Dementia Prevention&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Is Primary Prevention of Dementia Possible?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - The control of vascular risk factors (high blood pressure [HBP], diabetes mellitus [DM], hypercholesterolemia) and healthy lifestyle habits (consumption of omega-3 fatty acids, physical and mental exercise) is recommended due to the clear evidence that exists about its benefit on other aspects of health, although its possible benefit on the reduction of the risk of dementia is not supported by appropriately designed studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Although moderate alcohol consumption or chronic consumption of NSAIDs has been associated with a lower risk of Alzheimer's dementia (AD), they also have other risks for health and there is not enough evidence to recommend them in the prevention of dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Neither the intake of vitamin C nor vitamin E nor hormonal replacement therapy are recommended to prevent dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Genetic Study in Dementias&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;When Are Genetic Analyses Indicated to Identify Pathogenic Mutations in Patients with Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Patients with a likelihood of suffering dementia due to genetic causes should be referred to specialist genetic counselling units.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Performing genetic analyses to detect causal mutations is indicated in patients with AD and an autosomal, dominant family history of pre-senile onset.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - In patients with frontotemporal lobar degeneration (FTLD), genetic analyses would be indicated in cases with a family history of a similar disease.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - In patients with prion diseases, the genetic study would be indicated in all cases, regardless of family history or age.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The genetic study is recommended if Huntington&amp;rsquo;s disease is suspected, to confirm the diagnosis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;According to Applicable Legislation&lt;/strong&gt; - The execution of genetic analyses in clinical practice must be authorised in writing by the actual individual or his/her legal representative after receiving genetic counseling.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;When Is a Predictive Genetic Analysis Indicated in Asymptomatic Individuals?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - The predictive genetic study can be performed on people of full legal age who are at a risk of being carriers of a pathogenic mutation known to cause dementia and who wish to have it conducted, following informed written consent and multidisciplinary genetic counselling prior to the genetic analysis and subsequent monitoring.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The study of genetic risk factors of dementia, such as the apolipoprotein E (APOE) genotype, is not indicated for genetic counselling purposes in asymptomatic individuals.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Dementia Diagnosis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;How Is Dementia Diagnosed?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - The assessment of the impact of cognitive impairment on the activities of daily living is recommended, given their affectation, which forms a dementia diagnostic criterion and determines the subsequent management of these patients.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - Obtaining data from an independent and reliable informant is recommended, whenever possible.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - An assessment of the psychological and behavioural symptoms is recommended, due to their importance for the diagnosis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - The execution of a general physical and neurological examination of patients with dementia is recommended to detect comorbidity and associated neurological signs that may help towards the differential diagnosis of some subtypes of dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The use of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) and International Classification of Diseases and Related Health Problems, 10th edition (ICD-10) clinical criteria is recommended to diagnose dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The use of DSM-IV-TR or National Institute of Neurological Communicative Disorders and Stroke/Alzheimer Disease and Related Disorders Association Work Group (NINCDS/ADRDA) criteria is recommended to diagnose AD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The use of National Institute of Neurological Disorders and Stroke/Association Internationales pour la Recherche et l'Enseignement en Neurosciences (NINDS/AIREN) criteria or the Hachinski scale is recommended to facilitate the diagnosis of vascular dementia (VD).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The use of Emre et al. (Movement Disorder Society) criteria is recommended to diagnose Parkinson's disease dementia (PDD).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The use of McKeith criteria is recommended to diagnose dementia with Lewy bodies (DLB).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The use of Lund-Manchester or Neary criteria to help diagnose FTLD is recommended.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Are the Advantages of Neuropsychological Testing Assessment in Cognitive Impairment and Dementia?/What Neuropsychological Tests, Questionnaires or Functional Evaluation Scales Must Be Performed on Patients with Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Patients with cognitive complaints must be assessed by means of global cognition screen tests, neuropsychological test batteries, short cognitive instruments focused on specific aspects of cognition and/or standardised structured questionnaires to quantify the degree of cognitive impairment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - The dementia diagnosis must include a formal objective cognitive assessment with validated instruments.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - The use of the Spanish standardised version of the Mini Mental State Examination (MMSE) or the Mini Examen Cognoscitivo (MEC) is recommended to screen dementia in individuals with cognitive complaints or advanced age in our medium.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Other short screening tests, such as the Pfeiffer test, the Memory Impairment Screen (MIS), the 7-minute test, the clock test, the Eurotest or the Memory Impairment Test (T@M) can also be recommended to screen dementia in individuals who are suspected of having cognitive impairment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The neuropsychological examination using general brief-intermediate type evaluation tests is recommended when the aim is to make an evaluation of the most important neuropsychological areas in a reasonable time.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The performance of a detailed neuropsychological assessment via specific tests is recommendable when there are differences between the clinical impression and the screening tests, diagnostic doubts or else when the complaints are limited to just one cognitive domain or evolve over a short period of time.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - The use of specific scales is recommendable to quantify the degree of global functional impairment in individuals who are suspected of having cognitive impairment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - The choice of a specific instrument must be made depending on the time available, on the clinical experience and on the availability of regulatory data in the language and in the medium where they will be applied.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Which Laboratory Tests Are Essential in Diagnosing Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The performance of the following laboratory tests is recommended in all patients assessed for possible dementia: haemogram, thyroid-stimulating hormone (TSH), electrolytes, calcium and glucose, to rule out potentially reversible causes of dementia and to screen comorbidities.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The determination of folate levels can also be added, especially in patients with limited intake of cereals, and levels of B&lt;sub&gt;12&lt;/sub&gt;, above all in older adults.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Serologies are also recommended for syphilis or human immunodeficiency virus (HIV) only in patients with clinical suspicion of these infections as a potential cause of dementia or as comorbidity.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The determination of homocysteine as a risk factor associated with cognitive impairment or AD is not recommended.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Must the Determination of Apolipoprotein E (APOE) Be Requested?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - The determination of the APOE genotype is not recommended in healthcare practice to diagnose AD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Are the Advantages of Analysing Cerebrospinal Fluid (CSF) in the Diagnosis of Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The determination of T-tau, A&amp;beta;-42 and P-tau in CSF can be used as an additional test in cases of doubtful differential diagnosis between AD and other dementias. Its routine use is not recommended to diagnose dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The determination of T-tau, A&amp;beta;-42 and P-tau in CSF can be used as an additional test in cases of mild cognitive impairment when the clinical, neuropsychological and evolving features lead to AD being suspected as an aetiology of such impairment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - The 14-3-3 protein test in CSF is recommended when Creutzfeldt-Jakob Disease (CJD) is suspected.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt;- CSF analysis must always be performed whenever dementia secondary to an infection or encephalitic process is suspected.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Which Is the Structural Neuroimaging Technique of Choice in the Diagnostic Process of Dementia and Its Different Types?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Structural neuroimaging (computed tomography [CT] and magnetic resonance imaging [MRI]) is recommended as a supplementary tool in the initial diagnosis of dementia, above all to identify lesions that can be treated by surgery and vascular diseases.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt;- MRI is recommended to detect vascular changes with greater sensitivity than CT.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The execution of an MRI with diffusion sequences is recommended if CJD is suspected.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Which Is the Functional Neuroimaging Technique of Choice in the Diagnostic Process of Dementia and Its Different Types?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Single-photon emission computed tomography (SPECT) and positron emission tomography (PET) can be used as a complement to structural neuroimaging to support the diagnosis or to help differentiate between different types of dementia when the diagnosis is uncertain. Its routine use or its use as a sole diagnosis tool is not recommended.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The &lt;sup&gt;123&lt;/sup&gt;I-FP-CIT SPECT is recommended to support the diagnosis of DLB (as a suggestive diagnostic feature) and for the differential diagnosis between DLB/PDD and AD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Are the Advantages of Electroencephalogram (EEG)/Mapping in the Diagnosis of Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The execution of an EEG is recommended if the presence of delirium, complex partial epileptic crises or non-convulsive status epilepticus is suspected.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - The use of EEG to diagnose CJD is recommended.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Are the Indications for Performing a Cerebral Biopsy in the Aetiological Diagnosis of Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The execution of a cerebral biopsy for diagnostic purposes must only be considered in highly selected patients when a reversible cause is suspected that cannot be diagnosed in any other way.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Different Healthcare Level Actions&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Role Does Primary Care Play in the All-Round Care of Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The primary care team (PCT) professionals must suspect the existence of cognitive impairment and/or dementia if they observe memory complaints, behavioural changes and difficulties to carry out advanced and instrumental activities of daily living (ADL), carrying out screening tests and starting complementary examinations to be able to formulate a diagnosis and refer to the specialized dementia care team (SDCT) depending on the results.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Must Dementia Screening Be Carried Out in the General Population?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - There is not enough scientific evidence to permit the recommendation of population-based dementia screening in people over the age of 65.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Are the Criteria for Referring to Specialist Dementia Care (SDC)?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - The PCT is advised to refer people to the SDCT who have: a) early family or genetic onset dementia, b) doubts in the diagnosis of cognitive impairment, c) potentially severe secondary dementia, d) suspicion of neurodegenerative disease, e) unpredictable or difficult to manage complications in the course of already diagnosed dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The referral of patients with MCI or secondary dementia that can be solved by the PCT, or pluripathological patients with bad functional basic status, is not recommended.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Monitoring Must Be Carried Out by Primary Care on Patients with Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The PCT must assume responsibility for the management, care and monitoring of people with dementia and of their caregivers.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - People with predictable evolution must be periodically controlled by the PCT. If there is unexpected worsening, alarm signals, behavioural crises, etc. they must be quickly attended by PCT, and they are difficult to control, they must be referred to the SDCT.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Coordination and communication between PCT, SDCT, Social-Health Care (SHC) and Association of Families with Alzheimer's Disease (AFA) must be established to guarantee healthcare continuity throughout the entire process.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Which Specialised Care Teams Are Required to Address Dementia (SDCT) and What Role Do They Play?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is recommendable for the multidisciplinary team of the SDCT to include an expert specialist physician in dementia (neurologist, geriatrician or psychiatrist), a psychologist/neuropsychologist, a nursing professional, a social worker and administrative staff. The SDCT must have access to diagnosis means to be able to design treatment, monitor strategies and satisfy their healthcare, teaching, research and management objectives.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Patients and/or their families must be informed about the diagnosis, the prognosis and the strategy to be followed.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Patients and/or their families must receive a written report listing all the examinations carried out, the diagnostic guideline and treatment, and monitoring plan. This information must be given to the PCT and/or to the referring practitioner.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Is the Role of the Social-Health Network in a Comprehensive Approach to Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The existence of specific resources is recommendable to care for people with dementia, and the SHC network must have specific resources that adapt to each stage of the disease.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - To optimise the comprehensive treatment of dementia, it is recommendable for there to be referral, admission and discharge criteria for each healthcare resource.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Treatment in specific day hospitals for dementia is recommended in mild and moderate phases of dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Role Do Mental Health Services Play in the Care of Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - It must be taken into account that the mental health services carry out an essential role in the care of people with dementia, as they contribute to the aetiological diagnosis, the treatment and hospitalised care if severe behavioural and psychological symptoms of dementia (BPSD) appear. They provide coordinated, comprehensive and multi-disciplinary care.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Which Social Services Are Involved and What Role Do They Play in the Care of People with Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is recommendable for health and social services professionals to have a knowledge of the problems that affect their dementia patients to be able to provide an answer to their demands and know what tasks caregivers must carry out, the time they spend, the environment where they live, and the cost it represents for the family.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The Administration, through its social services network, must adapt to the increase in demand for care and services for people with dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Favouring access to social services is recommendable as well as providing the services to give adequate support to the task of caring of families that care for people with dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is recommendable to step up the support measures to make it easier for people with dementia to remain at home.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Psychological support and psychoeducational interventions geared towards families with people with dementia are recommendable, in order to favour their task of caring, reduce the care burden and improve the quality of life.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - In each case and depending on the moment of evolution of the dementia, it is recommendable to dynamically select the best social service resource that must be provided to a family caring for a person with dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;How Must the Care Continuity between the Different Dementia Healthcare Levels Be Coordinated and Guaranteed?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - To ensure seamless social and health care in the care of people with dementia and their families, it is recommendable, throughout the entire process, for there to be coordination between the different care levels, social services and community resources.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - To favour the comprehensive care of the person/family with dementia, it is recommendable for the communication and coordination between the different levels (health, social and community) to be fast, efficient, effective and multidirectional.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is recommendable for all the care levels to collaborate in obtaining a fail-safe diagnosis, favouring the obtaining of biological and neurological tissue samples.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Coordination at the different healthcare levels is recommendable in order to favour respect for the rights and freedoms of patients in decision-making (advance directives).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Coordination between the healthcare levels, the SDCT, universities, pharmaceutical industry, teaching and research institutions and the AFA is recommendable to favour an increase in knowledge (training and research) of dementias (health, social, community aspects).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is recommendable for the different professionals who intervene in the care of dementia to collaborate in drawing up a record of dementias to have a better knowledge of reality and rationally plan new intervention strategies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Dementia Treatment&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;General Measures&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;When and How Must Patients and Their Families Be Informed of the Dementia Diagnosis?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Informing patients and their families of the dementia diagnosis is recommended when there is reasonable suspicion of dementia. The SDCT physician and/or PCT are the people who must inform.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Informing patients who request this and their families of the diagnosis is recommended; as it has been proven that the information received does not predispose or generate a disorder in the person affected.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The patients' right to be informed or not must be respected, as well as their right, if they are capacitated to do so, to choose those people around them who must be informed of the process.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Offering information via understandable, sensible, respectful, empathic, verbal communication, and an adequate environment and conditions is recommended, to facilitate two-way dialogue. To make it easy to understand the diagnosis and its consequences, further information can be provided via information leaflets, booklets, videos, Internet and other audiovisual means and the AFA. If there are language barriers, communication must be facilitated through an independent cultural mediator.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The individual evaluation of the possible impact that communicating the diagnosis may generate is recommended, as well as doing so in instalments if necessary, providing further information during successive visits and in information sessions (SDCT, PCT, AFA).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Basic Content Must the Information Given to Patients and Family Have?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Giving information to patients and families about dementia is recommended, as well as about its evolution, clinical manifestations, comprehensive treatment and support to the caregiver, which will enable them to plan their future.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is advisable for the group information sessions aimed at families to contemplate basic aspects of dementia; function of the different professionals and healthcare levels; comprehensive treatment and available resources; management of emerging problems; detection of burdens derived from the task of caring, and support to the caregiver.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The execution of specific training programmes for families who live with people affected by DLB, FTLD or VD and in advanced or terminal dementia stages is recommended.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Training health practitioners, social services professionals and volunteers/professionals is recommended so that they can manage a group of patients and/or families affected by dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is recommendable to train caregivers (families or professionals) to empower them to manage non-pharmacological interventions of dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Specific Pharmacological Treatment of Dementia&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Is There a Specific Pharmacological Treatment for Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - ACE inhibitors are recommended for the specific and symptomatic treatment of mild to moderate AD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - Treatment with ACE inhibitors is recommended to manage mild to moderate VD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - ACE inhibitors have proved to be beneficial in dementia by DLB and PDD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - No differences have been shown regarding different ACE inhibitors (donepezil, rivastigmine and galantamine) in respect of efficacy and safety.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - Memantine is recommended as specific treatment for moderate to severe AD in monotherapy or combined with ACE inhibitors.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Is the Specific Pharmacological Treatment Equally Effective in All People?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The guideline developers have little evidence about whether specific pharmacological treatment is just as effective in all people due to the lack of studies that assess the individual response to different drugs.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Which Specific Pharmacological Treatment Is Effective in the Treatment of Mild, Moderate and Severe Alzheimer's Disease?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - Treatment is recommended with ACE inhibitors (donepezil 5-10 mg/day, galantamine 16-24 mg/day or rivastigmine 6-12 mg/day oral/4.6-9.5 mg/day transdermal) in patients with mild or moderate AD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - An ACE inhibitor can be used (donepezil or galantamine) in severe AD, although there is less evidence of its benefit.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - Treatment with memantine is recommended, at a dose of 20 mg/day in patients with moderate to severe AD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Which Specific Pharmacological Treatment Is Effective in Cognitive, Behavioural, Functional Manifestations and/or Quality of Life in AD?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - Treatment with ACE inhibitors is recommended in patients with mild to moderate AD, to manage the cognitive and functional symptoms.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - Treatment with ACE inhibitors is recommended in patients with mild to moderate AD, to manage behavioural alterations (apathy, anxiety and depression), despite the benefit being modest.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - Treatment with memantine is recommended in patients with moderate to severe AD, to manage the cognitive and functional symptoms.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - There is no evidence to recommend treatment with ACE inhibitors to improve the quality of life of patients with AD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Adverse Effects and Contraindications Exist for the Specific Pharmacological Treatment in Alzheimer's Disease?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - Following the indications of the technical data sheet of the drug it is recommended to assess adverse effects and contraindications of the ACE inhibitors and memantine.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The administration of a progressive dose of the drug is recommended to avoid or reduce the adverse effects of the ACE inhibitors, starting the treatment at low doses, to reach the optimal tolerated therapeutic dose.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - ACE inhibitors must be used with caution in patients with a background of epilepsy, asthma or obstructive lung disease, arrhythmias, syncopes, low blood pressure, presence of bradycardia or long QT, active peptic ulcer, urinary retention, renal or hepatic insufficiency. Memantine must be used with caution in patients with a background of epilepsy, renal insufficiency and urinary retention.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Domperidone can be used to treat mild gastrointestinal effects secondary to ACE inhibitors.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;How Effective and Safe Is the Combination of Two or More Specific Drugs in Mild, Moderate and Severe Alzheimer's Disease?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The addition of memantine is recommended in patients with moderate to severe AD, treated with donepezil at stable doses in combined therapy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The addition of memantine to donepezil is not recommended to treat patients with mild to moderate AD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;When Must Specific Pharmacological Treatment in Alzheimer's Disease End?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - Individual assessment of the suspension of specific pharmacological treatment is recommended, as the guideline developers have no studies that assess this item, and in the only study where the treatment with donepezil was interrupted, neither cognition nor function returned to the level achieved before the interruption.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Specific Pharmacological Treatment Is Effective in Parkinson's Disease Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The use of rivastigmine is recommended in PDD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The use of donepezil may be considered to treat cognitive and functional symptoms in PDD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - There is not enough evidence to recommend the use of memantine in PDD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Adverse Effects and Contraindications Exist in the Specific Pharmacological Treatment of Parkinson's Disease Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - In patients affected by PDD, treatment with donepezil and memantine is associated with a rate of adverse effects similar to the placebo group, unlike with rivastigmine, which showed a higher rate of side effects, an increase in tremors and a lower rate of mortality than the placebo group.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Specific Pharmacological Treatment Is Effective in Dementia with Lewy Bodies?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The use of rivastigmine is recommended to treat BPSD in DLB.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - The use of donepezil or galantamine may be considered to treat cognitive symptoms and BPSD in DLB.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - There is no evidence to recommend the use of memantine in DLB.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Adverse Effects and Contraindications Exist in the Specific Pharmacological Treatment of Dementia with Lewy Bodies?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - The most frequent adverse effects observed in treated patients with DLB are: nausea, vomiting, weight loss and drowsiness. These were more frequent in patients treated with rivastigmine compared to placebo. Those treated with memantine compared to placebo had the same adverse effects. The potential adverse effects of rivastigmine must be detected and monitored during treatment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;How Useful Are Drugs with Dopaminergic Action in Dementia with Lewy Bodies?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Levodopa can be used in monotherapy to treat the motor symptoms of DLB.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is advisable to avoid the use of dopaminergic and anticholinergic agonists in DLB due to their potential effect of worsening the cognitive and psychotic symptoms and producing sleep alterations and orthostatic hypotension.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Which Pharmacological Treatment Is Effective in Cognitive and Behavioural Manifestations of Frontotemporal Lobar Degeneration?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The use of ACE inhibitors or memantine to treat cognitive-behavioural symptoms of patients with FTLD is not recommended.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The use of selective serotonin reuptake inhibitors, trazodone or atypical neuroleptics is recommended to treat agitation, inappropriate behaviour, compulsions or stereotypies in patients with FTLD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Which Specific Pharmacological Treatment Is Effective in Mild, Moderate and Severe Vascular Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - The use of ACE inhibitors is recommended in mild to moderate VD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - ACE inhibitors are recommended to improve the cognitive symptoms of mild to moderate VD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - Donepezil is recommended to improve the global clinical impression and functional deficiencies (ADL) in VD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - The use of galantamine is recommended to treat cognitive symptoms, functional deficiency and BPSD in patients with mild to moderate VD, mixed dementia and/or AD with cerebrovascular disease.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Rivastigmine may be used to improve cognition in VD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - Memantine may be used to treat cognitive symptoms of moderate and severe VD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Influence Does Specific Pharmacological Treatment Have on Vascular Dementia with Respect To Cognitive, Behavioural, Functional Manifestations and/or Quality of Life?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - ACE inhibitors may be used to treat cognitive symptoms of VD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - ACE inhibitors and/or memantine are not recommended to manage behavioural symptoms in VD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Adverse Effects and Contraindications Exist in the Pharmacological Treatment of Vascular Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - Bearing in mind that patients with VD usually suffer a high cardiovascular risk, treatment with ACE inhibitors should be assessed individually, paying special attention to how the treatment is managed.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - It is advisable to follow the indications given in the product technical data sheet.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Are Any Other Pharmacological Treatments Effective to Treat Cognitive and Functional Functions in People Affected by Any Type of Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Hormone Treatments&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - Hormonal therapies (adrenocorticotropic hormone [ACTH], prednisone, oestrogens, dehydroepiandrosterone) are not recommended as treatment of AD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;NSAID&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - Neither ibuprofen, indomethacin nor low doses of naproxen are recommended to treat AD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Piracetam&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - Piracetam is not recommended to treat AD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Propentofylline&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - Propentofylline is not recommended to treat AD or VD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Nimodipine&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Nimodipine is not recommended to treat VD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Selegiline&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - Selegiline is not recommended to treat AD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Ibedenone&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - Ibedenone is not recommended to treat AD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Dihydroergotoxine Mesylate&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Dihydroergotoxine mesylate is not recommended to treat AD or VD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Citicoline or Cytidine Diphosphate-Choline (CDP-choline)&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The oral administration of neither citicoline nor CDP-choline is recommended to treat VD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The parenteral administration of neither citicoline nor CDP-choline is recommended to treat vascular cognitive impairment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Non-pharmacological Treatment of Dementias&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Are Cognitive Intervention Programmes Effective in Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The participation in cognitive intervention programmes is recommendable in patients with mild or moderate AD, to maintain their cognitive function, their functionality and quality of life, although the magnitude of the effect attributable to the actual cognitive intervention is not well established.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - There is currently no evidence of the efficacy of cognitive stimulation in individuals with VD to recommend its use in this dementia subtype.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A type of specific cognitive intervention cannot be recommended at the present time, based on the degree of efficacy in patients with mild or moderate AD, although interventions that require a general processing type seem to have a greater overall benefit than those where cognitive training of specific functions is carried out.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Are Computer-based Cognitive Intervention Programmes Effective in Patients with Alzheimer's Disease?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - The use of computer-based cognitive intervention programmes in initial AD or mild cognitive impairment cannot be recommended at the present time.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Are Individual Cognitive Interventions Recommendable?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Individual cognitive interventions are recommendable to stabilise the cognitive function and functionality of individuals with AD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The use of individual interventions rather than group interventions cannot be recommended or vice versa.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Do Intervention Programmes on Activities of Daily Living Improve the Functionality of People with Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Intervention programmes on ADL are recommended to improve the functionality of patients with dementia and decrease the strain on the caregiver in the medium term, both in institutionalised individuals and individuals who live in their family homes.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Are Physical Activity Programmes Effective in Improving or Stabilising the Functional Capacity and Cognitive Functions of Patients with Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Long-term physical activity programmes are recommended to maintain the functionality of institutionalised patients with dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Are There Any Other Non-pharmacological Treatments That Are Effective in Cognitive, Functional, Motor and/or Quality of Life Manifestations in Dementias?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - The use of therapeutic touch massages, transcutaneous electrical nervous stimulation, music therapy or multi-sensory therapy cannot be recommended at the present time to treat cognitive or functional manifestations in patients with dementia or specifically with AD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Behavioural changes, programmed hygiene and induced urination are recommendable to reduce urinary incontinence in individuals with dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;May Non-pharmacological Treatments Used in Dementia Have Harmful Effects?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - Cognitive intervention programmes, especially those based on reality counselling therapies and cognitive training, must be adapted to the cognitive skills and to the emotional tolerance of each patient, in order to avoid adverse emotional consequences.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment of Behavioural and Psychological Symptoms of Dementia&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Why Are BPSD Important in Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - The systematic assessment of the presence of BPSD is recommended as it is a fundamental component of the clinical picture, it appears very frequently, it is difficult to manage, it has an impact on the quality of life and is a frequent reason for urgent care, family claudication and institutionalisation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;How Can the Intensity and Frequency of BPSD Be Quantified?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - The use of specifically designed instruments is recommended to evaluate BPSD in dementia independently from cognitive and functional alterations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - Neuropsychiatric Inventory (NPI) is recommended as an instrument to assess the intensity and frequency of BPSD, the Cornell Scale for Depression in Dementia (CSDD) to assess depressive symptomatology and Cohen Mansfield Agitation Inventory (CMAI) to assess agitation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;At What Moment in Time Do BPSD Appear in the Evolution of Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - It is advisable to bear in mind that BPSD may appear at any time during the evolution of dementia, whatever its aetiology, and it is not unusual for it to be the first manifestation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - If delusions and hallucinations appear in a person with early stage dementia, FTLD or DLB must be suspected. If there are rapid-eye movement (REM) sleep behaviour disorders, the first suspicion will be DLB.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Are There Some BPSD That Are Characteristic of Some Types of Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - BPSD must be detected as soon as possible, in mild dementia stages, or throughout its subsequent evolution; they must be quantified and grouped into syndromes that facilitate differential diagnosis between the different dementias.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - It is advisable to know and recognise the BPSD that appear in AD, VD, FTLD, DLB and PDD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Which Non-pharmacological Measures Are Indicated in Each BPSD in Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - Starting treatment with non-pharmacological strategic measures to manage BPSD is recommended.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - It is especially important for caregivers to receive information and training that capacitates them to prevent the appearance of BPSD and act as co-therapists when they are already present.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Stimulation-oriented treatment with recreational activities and pleasurable activities have proved to be effective to cope with depression.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - Non-pharmacological sleep management mainly consists of establishing guidelines and good sleep hygiene.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - There is limited evidence that therapeutic massages may be effective to treat agitation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The use of electronic identification techniques on dementia patients who present erratic wandering is recommended.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Are the General Recommendations for the Pharmacological Treatment of BPSD?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The target symptom that must be treated as well as its possible causes or triggers must be identified.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The general recommendation respect to pharmacological treatment of BPSD is to start with ACE inhibitors and/or memantine and, if the response is not sufficient, add a psychotropic drug.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - Bear in mind the special sensitivity of these patients to adverse effects, especially the risk of anticholinergic effects, orthostatic hypotension, falls, extrapyramidal effects, worsening of cognitive function, confusion and delirium. Start with low doses and slowly reach the minimum effective doses. Preferential use of oral route.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - Review the dose and the actual treatment need at regular intervals, generally every 3 months.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;ACE Inhibitors and/or Memantine&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The use of ACE inhibitors and/or memantine is recommended as treatment of dementia, not only for cognitive symptoms but also for non-cognitive ones.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The use of rivastigmine is recommended to treat BPSD in patients with DLB or PDD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Psychotropic Drugs&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The use of psychotropic drugs is recommended to treat BPSD, although evidence about their efficacy in patients with dementia is generally low and the risk of adverse effects is high.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Is the Optimal Pharmacological Treatment for Each BPSD?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;ACE Inhibitors or Memantine&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The use of these drugs in patients on whom the use of ACE inhibitors or memantine is indicated is recommended for the initial pharmacological treatment of BPSD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Donepezil may be used in patients with AD and psychotic symptoms. Rivastigmine may be used to treat psychosis in DLB.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - If the ACE inhibitors and/or memantine are not effective on the BPSD, the most adequate psychotropic drugs will be used for each type of symptom, considering their adverse effects.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Antipsychotics&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - Risperidone may be used in patients with AD and psychotic symptoms.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Atypical antipsychotics may be used in patients with AD or VD and psychotic symptoms.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Antidepressants&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Antidepressants, preferably sertraline and citalopram, may be used in patients with dementia and depression. Tricyclic antidepressants are not recommended due to their adverse effects, despite their similar effectiveness.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Apathy&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Psychostimulants, amantadine, bromocriptine or bupropion may be used in patients with dementia and severe apathy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Anxiety&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;There is not enough evidence to make recommendations about the treatment of anxiety in dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Erratic Wandering&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Risperidone may be effective in erratic wandering in AD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Sleep Problems&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Benzodiazepines, trazodone or hypnotics may be used to treat sleep disorders in dementia. Melatonin is not recommended.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Agitation and Aggressiveness&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The use of neuroleptics is recommended to treat agitation and aggressiveness. The evidence is greater for risperidone than for other drugs.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - In the case of intolerance to antipsychotics, donepezil (if indicated), selective serotonin reuptake inhibitor (SSRI) or carbamazepine may be used to treat agitation and aggressiveness.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Inappropriate Sexual Behaviours&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Antidepressants, antipsychotics, mood stabilisers, hormonal agents, cimetidine or pindolol may be used to treat inappropriate sexual behaviours.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Adverse Effects and Contraindications Do Drugs Used to Control BPSD Have?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - Antipsychotics must be used with caution in patients with dementia, due to the risk of adverse reactions, always considering the risks of treating compared with the risks of not treating.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Antipsychotics are contraindicated in DLB due to the high risk of adverse effects.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Treatments with benzodiazepines must be short-term due to the adverse effects.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;How Effective Is It to Combine Pharmacological and Nonpharmacological Treatment to Treat Behavioural and Psychological Symptoms in Mild, Moderate and Severe Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - The association of non-pharmacological and pharmacological measures is recommended to treat behavioural and psychological symptoms of dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Which Are the Most Effective Recommendations to Avoid BPSD in Patients with Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - A meticulous assessment is recommended if BPSD appear, to rule out concomitant pathology and achieve optimal environmental surroundings.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - Sensory stimulation, behavioural therapy, structured activities and social contact may be used to reduce the incidence of BPSD, although there is no scientific evidence to support this.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;How Must BPSD, Which Are Difficult to Monitor in Outpatients, Be Treated?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - If the behaviour crises do not respond to the normal pharmacological measures in the home/residence, admission into hospital or into specific units is advised to diagnose the symptoms and aetiology, treat comorbidities, optimise the treatment of BPSD and guarantee the safety of the patient and of his environment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Attitudes Must Caregivers Satisfy to Deal with Patients With BPSD?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - It is advisable to inform and train caregivers of dementia patient in strategies to address and manage the BPSD so that it is possible to adopt and promote an appropriate attitude towards patients and prevent strain and claudication of the caregivers.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Alternative Treatments of Dementias&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Are There Any Plant-based Medications or Food Supplements That Have Proved to Be Useful in the Treatment of Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Vitamin E&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Vitamin E supplements are not recommended in the treatment of AD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Vitamin B&lt;sub&gt;1&lt;/sub&gt;, B&lt;sub&gt;6&lt;/sub&gt;, B&lt;sub&gt;12&lt;/sub&gt; and Folic Acid&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - The use of vitamin B&lt;sub&gt;1&lt;/sub&gt;, B&lt;sub&gt;6&lt;/sub&gt;, B&lt;sub&gt;12&lt;/sub&gt; or folic acid supplements is not recommended in patients with cognitive impairment that do not present a clear deficiency of these elements.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Copper Supplements&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The use of copper supplements is not recommended to treat patients with AD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Gingko Biloba&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - There is not enough evidence in literature about the efficacy of ginkgo biloba to recommend its use in the treatment of AD or VD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Lecithin, Alpha-lipoic Acid, Omega-3 Fatty Acids, Ginseng or Yokukansan (TJ-54)&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Existing evidence does not permit recommending the use of lecithin, alpha-lipoic acid, omega-3 fatty acids, ginseng or yokukansan (TJ-54) in the treatment of cognitive symptoms of AD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Assessment of the Treatment of Dementias&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;How Must the Response to the Treatment of Dementia Be Assessed in Clinical Practice?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The periodic assessment of cognitive, functional, motor and behavioural aspects is recommended, as well as of the degree of strain on the caregiver in the monitoring of patients with dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The use of tests, scales or questionnaires is recommended to quantify the therapeutic response and the appearance of complications in patients with dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - The choice of a test, scale or questionnaire will be based on the physician's experience and on its applicability in the context.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt;- The use of the MMSE is recommended to assess the response to dementia treatment in clinical practice.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Caregivers of Patients with Dementia&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Are the Characteristics of Caregivers the Same for People with Different Types of Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - During the care of every person with dementia, their individual characteristics and the actual characteristics of the disease must be evaluated to be able to evaluate and prevent the burden and needs of the caregiver, and act consequently to optimise their support network.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Repercussions Does the Care of a Person with Dementia Have on the Caregiver?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Dementia is a dynamic process which commits and compels the caregiver more. It is recommendable to meticulously evaluate the burden supported by the primary caregiver and the support he/she receives in their task of caring. If the burden is too much, it is advisable to establish the appropriate measures to prevent this from affecting his or her physical and psychological health, thus giving rise to the risk of claudication.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Scales Are Useful to Assess Caregiver Burden?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - The use of the Zarit scale (long and short versions) is recommended to quantify the caregiver burden.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - The use of specific adapted and validated instruments is recommended to assess other aspects they may be affected by the caregiver burden.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Are There Effective Interventions to Prevent Caregiver Burden?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - A basal evaluation of caregiver of a person with dementia is recommendable in order to identify the factors that affect the burden of caring, the difficulties that might arise in the course of the disease and the degree of burden that the caregiver already has at the time of the diagnosis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The caregiver should be informed well and progressively about the disease and its possible complications, offering him or her available social resources, as well as the formal or informal support systems to prevent strain.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Are There Effective Interventions to Deal with Caregiver Burden?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - To improve the care of caregivers of people with dementia and reduce their burden in the task of caring, as well as anxiety and depression, a programme that combines educational support, emotional support and the provision of resources may be beneficial.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt;- Interventions carried out in the caregiver&amp;rsquo;s own home and in a personalised manner are recommendable.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Comprehensive care of the caregiver must contemplate many different actions: Welcome programme, information sessions, theoretical and practical training, advisory services, emotional support, adaptation of resources, pharmacological treatment if required and accompaniment throughout the entire process.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Are Mutual Aid Groups (MAG)?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - There should be a professional in the MAGs to favour and foster the skills of the group members.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Benefits Are Obtained from Participating in MAG?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is advisable and desirable for the caregivers of people with dementia to participate in MAGs, as they provide many different benefits, which will enable them to cope better with the care work and improve their personal situation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Participation in therapeutic aid groups (TAGs) or educational and emotional support groups (EESG) to improve the strategies to cope with dementia is recommendable, relieving the burden and improving the level of anxiety and depression that might affect the caregiver.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Professionals that run the TAG or EESG must personalise their interventions to be more efficient.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;In What Cases Is Psychological Treatment of the Caregiver Necessary?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - It is recommended for those caregivers who express a significant degree of stress and/or depression to be referred to their primary care physician and/or mental health specialists for their assessment and treatment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Psychotherapy, especially cognitive-behavioural therapy, would be recommended to treat stress or depression due to strain of the caregiver when he or she presents clinically relevant symptomatology.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Are Associations of Families of People Affected by Dementia and What Role Do They Play in a Comprehensive Approach to Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Health practitioners and social services professionals who care for people with dementia and their families should comment on the existence of the AFAs and the benefits that they can obtain from them, and insist on their experience in living with people with dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - To achieve optimisation in the approach and management of dementia throughout the entire process, from diagnosis until after death, the existence of good coordination between the different healthcare levels and the AFAs is recommendable.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Must the Relationship between the Associations and the Health and Social Public Network Be Like?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - There must be a close relationship between the tertiary sector and the Public Administration with continuous dialogue, thus favouring the exchange of knowledge both on the needs and collaboration proposals (programmes, subsidies, agreements, etc.).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is recommendable to continue improving the relationship between the Public Administration and the AFAs to improve the quality of life of the people affected by dementia and their families, by drafting referral protocols, recognising the role of the AFAs in the training of caregivers and professionals; fostering the creation of TAG and/or EESG and therapeutic programmes (day hospital [DH], day care [DC], rehabilitation workshops) and aid for the development of complementary activities.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Early Onset or Pre-senile Dementia&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Must the Diagnostic Process in People with Early Onset Dementia Be Different to the Process of a Patient Who Is More Than 65 Years Old When the Disease Starts?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The use of neuropsychological test batteries validated for this age group is recommended in the assessment and characterisation of cognitive impairment in people with pre-senile dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The aetiological study of a patient with early onset dementia should also include the study of low incident causes in later age groups and atypical presentations of frequent dementias.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - It is recommendable for patients with early onset dementia to be assessed by professionals with experience in this age group and at centres that have the appropriate supplementary tests to carry out this study.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Is the Pharmacological Treatment of a Person with Early Onset Dementia Different to That of a Person with Late Onset Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - Although there is no scientific evidence in presenile dementia, it is advisable to follow the same therapeutic guidelines used for older people.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Is the Non-pharmacological Treatment Prescribed to a Person with Early Onset Dementia Different to That of a Person with Late Onset Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - It is advisable for people with presenile dementia to carry out the same nonpharmacological therapies that have proved to be effective in people over the age of 65.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - If we wish to favour their adherence to individual or group non-pharmacological therapeutic programmes, these must be adapted to the specific needs of the person with early onset dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Health and Social-Health Resources Do People with Early Onset Dementia Require?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - It is recommendable for patients with early onset dementia to have access to social-health and health resources that focus specifically on their care.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Ethics and Legal Aspects of Dementias&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Abuse of People with Dementia&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Is Understood by Abuse of People with Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is necessary for health practitioners, the social services and society in general to be concerned and become aware of the abuse that many elderly people suffer, whether they are affected or not by dementia. It is a personal, family, intergenerational, health problem, as well as one of justice and human rights. Its detection permits establishing prevention strategies, changes in attitude and the promotion of solutions.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;How Frequent Is Abuse in Dementia and What Are the Risk Factors?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Health and social services professionals must be trained and made aware to detect, declare, prevent and treat problems derived from the abuse of people with dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is important to identify the type of abuse (action or omission), and determine its characteristics (psychological, physical, sexual, economic).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - If abuse is suspected, the person must be questioned in private and with delicacy, given their fragility, bearing in mind their state of mind and fear of the consequences that discovery of abuse may entail, in their environment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - For a complete diagnosis of abuse, it is advisable to evaluate the risk factors, those that depend on the patient, on the abusing caregiver and the circumstances that surround it.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The possibility of the existence of abuse must be suspected, if the person with dementia is hostile, aggressive, provocative, dependent for ADL and there is a lack of an appropriate support network.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Caregivers must be suspected as abusers if health and social services professionals observe symptoms of anxiety, depression, strain in the task of caring, low cultural level and when the patient they are looking after is very dependent for ADL and/or presents BPSD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Intervention Strategies Exist to Detect a Case of Abuse?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - If the person has mild to moderate dementia, health and social services professionals must get them to give information about their physical and psychic state of health through fluent and true communication. In initial stages, this can be relatively easy to obtain; in fluctuating dementia, the most appropriate and reliable moment must be sought; in advanced stages, it will be possible to obtain information at moments of lucidity.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - A meticulous and thorough clinical examination is recommendable to detect signs that lead the health and social services professional to suspect the possibility of abuse, evaluating physical, psychological and behavioural aspects.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is advisable to be mindful of the possibility of abuse, as this facilitates its detection and permits protection, prevention and correction measures.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Health and social services professionals must systematically interrogate about aspects related to the abuse of any elderly person, with or without dementia, and use standardised scales to detect it.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Health and social services professionals must assess the caregiver of a person with dementia to detect a possible person responsible for abuse. Scales can be used to detect it.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Must Professionals Do When a Case of Abuse Is Detected?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Health and social services professionals must be trained to prevent, detect, care for, protect, declare and recuperate a person with dementia suffering from abuse.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - The fundamental rights of the person to dignity, participation, autonomy and self-determination must be preserved.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - People suffering abuse must be informed, respecting their right to confidentiality, in order to cover their basic needs, and right to preserve their social relationships.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - If there is probable suspicion of abuse, the health personnel must activate the judicial resources that permit the defence of the victim of abuse. If there are physical injuries, a judicial report of injuries will be drafted. If there are no injuries or other acute contingencies, the Public Prosecutor will be informed.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Social Resources Exist to Address Abuse?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - When abuse is detected and diagnosed, it is recommendable to launch strategies that permit improving the situation of the victim and of the aggressor. The actions of the different professionals must be coordinated, recording all the data of the abuse in the clinical record.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - To prevent and treat abuse, avoiding social isolation, optimising the patient's care, adapting their home and institutionalising them if the family cannot guarantee their care, are recommended.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is advisable to attend to the abuser, who is often a stressed or sick relative, or with an excessive burden. The burden can be reduced by sharing the task of caring, removing the patient from the family environment, participating in support groups, guaranteeing rest and offering medical treatment if required.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Advance Directives&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;When Must the Possibility of Drafting Advance Directive Documents (ADD), Living Wills and/or Granting Powers of Attorney Be Suggested to People with Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Health and social services professionals, and relatives must try to discover the ADD of the sick person to be able to comply with his or her wishes and respect his or her medical, legal and financial preferences.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is important to continue informing and raising the awareness of the population at large as well as of the health and social services professionals, about the need for able and free adult people to exercise their rights to draw up an ADD containing their wishes regarding the care and treatment they accept to receive, as well as the appointment of a valid representative that can decide on their behalf in each health circumstance, and after death, about the destination of their organs.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is advisable to draw up the ADD in adult age and being of sound mind. In respect of people with dementia, this must be attempted as soon as possible to guarantee their cognitive integrity to the utmost.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Health professionals must recommend the ADD to their patients, and insist upon it especially if they detect emerging cognitive impairment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is recommendable for the ADD to include everything that is important for the person, bearing in mind that another person, on whom they delegate, will have to decide in their name, following their own indications.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - To make it easier for a person to have access to the ADD, the ADD must be registered in the autonomous community and at the National Registry Office for advance directives or ADD of the Ministry of Health and Consumer Affairs, and it must be attached to the clinical record and to the health card.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Evaluation of Competences&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Are There Instruments That Have Been Strictly Designed to Assess the Competence of Patients with Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The utmost efforts should be made to maintain the autonomy of people affected by dementia, respecting their decision-making capacity, whenever possible, even at the end of their lives.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is recommendable for health and social services professionals, as well as the legal institutions that attend to them, to use a common language and share knowledge.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The decision capacity of any person affected by dementia should be assessed, using the assessment instrument of the Sitges 2009 document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is advisable to involve the patient, if possible, in decisions made about the treatment. The patient's desire must prevail; however, differences in opinion between patient and caregiver must be evaluated.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Total or partial incapacitation must be used as a legal resource to protect the person with dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - When carrying out a comprehensive and multidisciplinary assessment of a person with dementia, the evaluation of their decision-making capacity must be included, as well as if there is appropriate legal protection or not.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;How Are the Specific Competences Assessed: Driving Licence, Firearms Licence and Participation in Clinical Trials?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Driving Licence and Dementia&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The ability of people with dementia to drive a vehicle should be assessed, even during the initial stages, as an increase in the risk of suffering accidents has been proven.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - A full psychological evaluation should always be carried out at drivers' examination centres to detect people with cognitive impairment in mild dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Health professionals must inform patients with dementia and their families about the risk that continuing to drive may entail.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - If a person with mild dementia continues to hold a licence, their ability to drive must be reviewed every 6 to 12 months, or earlier if necessary, to evaluate their risk.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - A driving limitation must be proposed when alterations are detected in attention, orientation, executive functions or in visuospatial perception.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Firearms Permit and Dementia&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is advisable to keep firearms or elements that might be dangerous to them or to third parties, away from people with dementia, above all if there are behavioural disorders.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Research and Dementia&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - People with dementia and their relatives must be informed of the possibility of participating in clinical trials.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - People participating in research studies must receive extensive, detailed and understandable information, and they must sign an informed consent.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Good Clinical Practice Guidelines must be implemented in research studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The randomised controlled trial (RCT) should satisfy a series of conditions: a) correct methodology and competent research team; b) acceptable risk-benefit ratio; c) independent supervision; d) fair load distribution, random distribution, with equal probability of efficacy and safety in all groups; e) informed consent and confidentiality; f) safety guarantees; and g) appropriate payment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Professionals taking part in research studies must know about the agreements relating to human rights and biomedicine as well as the standards established by international ethical guidelines.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Which Are the Indications to Start the Legal Incapacitation Process of a Patient with Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is very important to respect the autonomy and freedom of the people at the time of the diagnosis and throughout the entire evolution process, bearing in mind that, despite the existence of advance directives, people, with age, due to circumstances and/or due to the actual disease process, may change their way of seeing things, and thus change their decisions.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Beginning the incapacitation process must be recommended when the dementia progresses and the cognitive and/or behavioural impairment determines taking inadequate decisions that might harm the person affected by dementia and their environment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The incapacitation process must be the result of a multidisciplinary evaluation, and must contemplate many different aspects such as: diagnostic, clinical manifestations, degree of dependence, social aspects, use of services, and evolution of the process.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Aspects Relating to the Patient's Legal Protection&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Does Legal Incapacitation Consist Of?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;According to Applicable Legislation&lt;/strong&gt; - To request the incapacitation or modification of the capacity to act, the procedure laid down by the Spanish Procedural and Civil Registration Law must be followed, whereby, based on a demand, the case is studied, opposed and the judge gives judgement.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Type of Legal Protection Exists for a Patient with Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - People with mild cognitive impairment and mild dementia should be advised to protect themselves through self-guardianship, or giving special power or writing the advance directive document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - Any person with dementia who still has sufficient capacity to act should appoint a guardian, foreseeing the possibility of being declared incapable, as well as adopt any provision referring to their personal care or the administration of their assets, identifying any person who should not be appointed, under any circumstances.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Is Guardianship?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - People with dementia who have lost their self-management capacity should have a legal representative or guardian to protect them, and substitute them.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - People with dementia with reduced decision capacity should name a representative who shall care for their conservatorship, accompanying them, advising them and helping them take decisions.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - People with dementia with reduced decision capacity should name an administrator for their estate to administer their assets if these were considerable.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - A judicial defender of the person with dementia must be named to cope with urgent situations if a tutor has not been named or when important differences arise between guardian and the ward.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Restraint of the Patient&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Are the Indications for Pharmacological and/or Psychological Restraint of a Patient with Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - It is recommendable to prevent and detect psychomotor agitation and aggressiveness of people with dementia at an early stage and treat it. The measures to be followed may be pharmacological or non-pharmacological, using mechanical restraint if required.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; - The use of atypical antipsychotic drugs is recommendable as first line pharmacological treatment of psychomotor agitation and aggressiveness of people affected by dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Are the Indications for Physical Restraint of a Patient with Dementia?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - When it has not been possible to control a person with dementia with pronounced psychomotor agitation using verbal and/or pharmacological measures, and they continue to be dangerous or at risk of causing harm to themselves or to others, mechanical restraint (MR) must be proposed.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Approved fastening elements must be used in the MR, in agreement with the legislation in force, and they must be in perfect conditions to be effective and safe.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - To achieve adequate and safe MR, a coordinated team is required, comprised of 4 or 5 well-trained people, who secure the patient properly, taking care not to harm him or her, and acting calmly and serenely, but firmly and surely. Throughout the entire treatment of MR, all those measures aimed at preventing direct or indirect complications must be maximised, guaranteeing the patient's comfort, privacy and respect. The MR measure will be stopped as soon as possible, and progressively, when the symptoms are under control.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - MR is a therapeutic physical restriction measure that must only be applied under medical prescription. It must only be used if other restraint methods are not applicable or have failed. Their objective is to protect the actual patient and other people, objects or surrounding environment. It cannot cause greater harm than the harm aimed to be avoided.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Excessive use of MR should be avoided in people with dementia, only using it when it is really justified, either due to the intensity of the symptoms and the possibility of them harming themselves or others. It must be as brief as possible to preserve the dignity and freedom of the person and reduce the risk of complications.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is advisable for the MR to be a shared decision, agreed upon by the other members of the interdisciplinary team. The parentage details, the type and date of application of the measure, the reason for the restriction, the care guideline to follow, the periodicity of the controls, as well as the information given to the patient and to the family, as well as the informed consent, must be described in the clinical record, and signed by the physician.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - The MR must be used in the following cases: to prevent injuries to the patients and to other people around them; to avoid interferences in the treatment (route, probes, etc.) and material damage to the patient's surroundings; to avoid escapes and prevent falls and maintain the correct position of the body; to achieve the centre's organisational objectives and maintain a comfortable social environment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - The contraindications of the MR must be respected and it must not be carried out if not explicitly indicated by the health professional responsible, or if, on the contrary, there are medical orders not to apply it. It must not be used, either, if there are equally effective alternative measures or procedures that have not been tried. They must never be used as punishment or as a show of force, or as a substitute for surveillance, or for the exclusive convenience or comfort of the professionals caring for them.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - It is advisable for the MR to be maintained for a short space of time (hours, days). With monitoring in order to guarantee adequate observation, to avoid risks and complications. When appropriate control has been achieved, it must gradually be brought to an end.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Are the Ethical and Legal Aspects of Restraint?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - As restraint measures affect people's freedom of movement, and their free of decision, and they are also not free from complications, before starting to apply them, the legal regulations that govern them must be carefully and strictly observed and enforced. The action must contemplate the principles of beneficence, non-maleficence and justice, and respecting the right to personal autonomy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;What Are the Indications for Involuntary Admission and What Process Must Be Followed?&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - People with dementia with severe behavioural disorders that entail a risk for the actual patient and/or for the people around them, and which are not adequately controlled in outpatients (primary and specialised care), should be admitted to control the crisis and enable the family to rest. Admission into these centres should satisfy the dual objective of diagnosis and treatment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Admissions in order to control crisis situations must be as short as possible, guaranteeing, at the time of discharge, that the symptoms have been controlled, that the environment and the receiving family are adequate, the caregiver's burden has been reduced and support measures for them to continue with their care work have been established.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;According To Applicable Legislation&lt;/strong&gt; - The legal regulation that protects people who are involuntarily submitted to admission into hospital must be respected. The opinion and consent of the family will be required as well as the judicial authorisation before carrying out the admission. The reasons must be suitably justified, ensuring their beneficence and respect for the dignity and freedom of the person affected.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - If involuntary internment is urgently required, for a person with dementia and severe behavioural disorders, it will be the physician attending to that person who shall take the decision. In this case, the person responsible at the centre must inform the competent court as soon as possible.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Care of People with Advanced Dementia and at End-of-Life Stage&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Which Criteria Define an Advanced and Terminal Situation with Prognosis of Limited Life in Patients with Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The term advanced and terminal situation of chronic disease with limited prognosis (SEAT) can be used in advanced degenerative dementia in terminal phase, which corresponds to stage Global Deterioration Scale (GDS) 7.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Evaluate the stage of SEAT using the Gold Standards Framework (GSF) instrument. The GSF is recommendable to find out the expectations of the caregivers regarding the death of the patient, the need to establish palliative measures, the limitation of the therapeutic effort, and about the consumption of resources, complications and crisis situations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Advanced dementia must be considered as terminal dementia if cognitive impairment is severe and there is severe dependence for the basic activities of daily living (BADL), there is no possibility of therapeutic benefit with the specific treatment, there is multiple comorbidity and a suitable nutritional status cannot be maintained.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Is It Possible to Determine, in People with Advanced Dementia at End-of-Life Stage, if Their Survival Is Going to Be Less Than 6 Months?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - To establish a life prognosis of less than 6 months in a person with advanced dementia, parameters with predictive power must be identified, such as degree of cognitive impairment, degree of functional disability, presence of malnutrition and presence of systemic complications and comorbidity.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;When Must Palliative Care Be Started on People with Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Palliative care (PC) must be implemented in the management of people with dementia, and this must be introduced early on after carrying out the diagnosis and it must be prolonged and increased as the disease progresses.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The aim of PC is to relieve physical and psychological suffering, provide quality of life and consider death as a natural process. Psychosocial and spiritual aspects must be integrated, giving support to relatives.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Health and social service professionals must be prepared to offer PC to people affected by dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Which Are the Most Suitable Health Resources to Care for People with Dementia at End-of-Life Stage?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - All people with advanced dementia must be provided with PC, whatever the healthcare level that is being applied.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Healthcare continuity must be maintained in PC when there is a change in the healthcare level of the person with advanced dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Health organisations should foster training of all professionals to provide basic PC.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Health organisations must guarantee accessibility to specialised PC when necessary.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Coordination between the different services and healthcare areas must be guaranteed, as well as continuity of palliative care.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;How Are the Clinical Manifestations and the Needs of People with Dementia and Their Caregivers Identified and Managed in the Advanced and Terminal Phase of the Disease?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Delirium&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Initial management of delirium must include the identification and treatment of the triggering causes, as well as appropriate information for relatives and caregivers, and an evaluation of the need to use pharmacological treatment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Haloperidol is the drug of choice for treating delirium in patients in terminal phase.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Benzodiazepines are effective in the management of delirium with marked agitation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The use of haloperidol and atypical antipsychotics must be avoided in patients with PDD and DLB, due to the risk of extrapyramidal reactions.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Depression and Anxiety&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - In people with advanced dementia at end-of-life stage due to a concomitant process, the diagnosis of depression must be based on the clinical observation, the information provided by relatives and, if possible, the use of specific scales.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - If necessary, antidepressant drugs, such as SSRI and tricyclics may be used, bearing in mind the possibility of central anticholinergic effects.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Psychostimulants such as methylphenidate, dextroamphetamine, modafinil and pemoline may have a fast response and are well-tolerated.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Dysphagia, Malnutrition and Dehydration&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Treatment of dysphagia requires individualised assessment of each case in order to identify and if possible, treat the cause.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The diet must be adapted to the clinical characteristics of the dysphagia. In the case of liquid dysphagia, thickeners may be effective. A soft diet that adapts as much as possible to the patient's tastes is recommended. If the patient collaborates, the adoption of postures that facilitate swallowing with the supervision of the speech therapist is effective.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Whenever possible, liquids must be administered orally.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The parenteral administration of liquids during the end-of-life phase must be carried out weighing up the advantages and disadvantages, and always after discussing it with relatives.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - The use of a nasogastric probe or permanent percutaneous gastrostomy must be assessed individually and with caution in patients with advanced dementia, as there is evidence of a bad relationship between benefit and risk.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Pain&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - The presence of pain must always be suspected in advanced dementia. This must be assessed through the patient's behaviour, the observation of relatives and the appropriate scales such as Pain Assessment Checklist for Seniors with Limited Ability to Communicate (PACSLAC) and DOLOPLUS.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The use of the World Health Organization (WHO) analgesic ladder guideline is recommended for the pharmacological treatment of pain in advanced dementia, and, if necessary, adding adjuvants.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Fever&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - It is recommendable not to treat pneumonia with antibiotics in a person with advanced dementia as it does not entail a benefit.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Hospital admission is not recommendable to treat pneumonia in a person with advanced dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Treatment with antibiotics is recommendable in people with advanced dementia who have breathing difficulties due to super-infection of bronchial secretions.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Pressure Ulcers&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - To prevent the appearance of pressure ulcers, there must be frequent changes in posture, using mechanical protections and maintaining a good state of nutrition, hydration and hygiene of the skin.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Psycho-emotional and Psychosocial Needs of People with Advanced Dementia and in End-of-Life Stage&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The psychosocial well-being of patients with life-threatening chronic diseases must be evaluated on a regular basis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The psychosocial assessment of patients in PC should include the following fields: aspects related to the moment in life, the meaning and impact of the disease, coping style, impact on the perception of oneself, relationships, sources of stress, spiritual resources, economic circumstances, doctor-patient relationship and social resources network.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Health and social services professionals attending to them should offer them basic emotional support.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - People with significant levels of psychological suffering should receive specialised psychological help.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Identifying and Evaluating the Psycho-emotional and Psychosocial Needs of People with Advanced Dementia and in End-of-Life Stage&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The team attending to people with dementia must bear in mind their beliefs and spiritual needs.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - In the absence of appropriate evidence about what is the best way to provide spiritual support, offering this support as an integral part of the care is recommended, whatever the care context, and with an approach based on the principles of effective communication.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is important to consider cultural differences with respect to spirituality, but this does not justify a lack of attention to these aspects in people who belong to different cultural or religious groups than those of the health care provider.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Psychosocial Support to the Family. Evaluate the Family and Social Needs&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - Caregivers must be offered the possibility of expressing their needs for support and information.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Identifying the most vulnerable or depressed caregivers is recommended in order to offer them intensive psychosocial support or specialised services.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Care of People with Dementia and Their Families during the Final Days of Their Lives&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Appropriate care during the final days of their lives should include:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Informing the family and caregivers of the situation of approaching death and, in general, provide the necessary information that adapts to their needs. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Explain and agree to the care plan with the patient, and whenever possible, with their families. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evaluate the medication the patient takes, suspending non-essential drugs, after explaining the reasons for this. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treat symptoms that produce suffering. The necessary drugs must be available if the patient is at home. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Interrupting unnecessary or futile interventions or tests, according to the patient's desires. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evaluate psychological, religious and spiritual needs of the patient, family and caregivers. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Provide care in a quiet atmosphere, respecting privacy and facilitating proximity with family and friends. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Provide the channels and resources necessary both for hospitalisation and for home care. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Needs Related to Death: Grief and Losses&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Referral of patients with complicated grief to specialised services (psychology, psychiatry, etc.) is recommended for them to receive specific and structured care.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Regular monitoring is recommended in risk grief, with emotional support, individually evaluating the need for specific and structured psychotherapies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Formal or structured interventions are not recommended in normal grief.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - In normal grief, providing information about the grief and about the available resources is recommended, as well as basic emotional support.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Professionals caring for patients at the end-of-life stage as well as their relatives, should have access to elementary training in grief, which will enable them to provide basic care to the grievers, understand and explore their needs, evaluate the risk factors, detect people with complicated grief and refer them to specialised service.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;How Can Worsening Due to the Natural Evolution of the Illness Be Differentiated from Worsening Caused by a Potentially Reversible Concomitant Process?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - In a person with advanced dementia, the existence of a concomitant process must be suspected if the progression suddenly speeds up and above all if there are unpredictable changes.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - When considerable worsening appears, regardless of the cause, a series of factors must be evaluated that may affect the therapeutic decision, always bearing in mind the values of the person and of the family.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is recommendable to evaluate the possibility of therapeutic limitation if the dementia has reached a very advanced stage: Functional Assessment Staging Tool (FAST) of over 7c in AD; when the Barthel index is 0; if the progression is very fast from the onset; if the infections are serious, repeated and with no relevant benefit with the treatment; if the dysphagia is problematic, with malnutrition and/or dehydration, and if there are refractory pressure ulcers.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Are the Objectives of Caring for People with Dementia in Terminal Phase?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Whatever the location, it is recommendable for patients with advanced or terminal dementia to receive palliative measures to improve their comfort, suffering and quality of life, insofar as this is possible.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Extraordinary or Greater Measures Should Be Questioned in the Care of People with Advanced Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Cardiopulmonary resuscitation is not indicated in people with advanced dementia, as it is an extraordinary therapeutic measure that does not provide any significant benefit.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - Neither artificial respiration nor dialysis are recommendable, either, in advanced dementia, because they provide no benefit.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Therapeutic Intermediate Measures Should Be Questioned in the Care of People with Advanced Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; - At the end-of-life phase of patients with advanced dementia, the use of intermediate range therapeutic measures (intravenous infusions, administration of antibiotics, artificial feeding, hospitalisation and execution of unnecessary diagnostic tests) is not recommended.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; - The use of intermediate range therapeutic measures should only be considered on those occasions when they can reduce suffering or they are the only available resource.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Information and Aid Must Be Provided to the Families of People with Terminal Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is recommendable to give information and support to caregivers of people with advanced dementia for them to continue assuming their work as caregivers, take decisions, adapt and engage more.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Informing and communicating bad news to the caregivers of people with dementia at the end-of-life stage requires adequate preparation of the professionals.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Legal Regulations and Ethical Principles Exist Relating to Communication with People with Advanced Dementia or with Their Families at the End-of-Life Stage?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - The participation of patients and caregivers in decision-making at the end-of-life stage must be fostered.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - If patients are not able to decide at this end-of-life stage, the advance directives expressed by them or their wishes included in the clinical record, or else the opinion of their legal representative and/or closest family, must be contemplated.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - Informing the team of the decisions adopted at this end-of-life stage is recommended, recording the process in the clinical record.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - If there are doubts during the decision-making process, other expert professionals (other professionals, healthcare ethics committee, etc.) should be consulted.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;In What Cases Is a Post-Mortem Pathoneurological Study Recommended?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; - It is recommended for the medical team attending to the patient at this end-of-life phase to request the post-mortem neuropathological study to confirm the diagnosis (above all in those cases where there is not an accurate diagnosis, or if a prion disease is suspected or any other disease of compulsory declaration) and foster the investigation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Diffusion, Training and Research in Care of People with Dementia&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;How Must the Topic of Dementias Be Dealt with in the Media in Order to Suitably Inform the Public, and Which Are the Most Appropriate Media?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - Information about dementia through the media must be based on ethical principles and good practice.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - The existence of specialised journalism in health issues is recommendable. The media, the competent professional associations and family associations must collaborate in fostering good information about dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Undergraduate Dementia Training Must Be Given to Health Sciences and Social Services Professionals?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - It is recommendable for health sciences university students to receive general dementia training, in aspects such as epidemiology, pathophysiology, clinical manifestations, diagnosis techniques, pharmacological and non-pharmacological treatment, on the needs of the patients and relatives, and resources available, as well as on associated ethical and legal aspects.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Dementia Training Must Be Given in Health Branches of Vocational Training?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - Health vocational training (VT) must guarantee the acquisition of theoretical and practical knowledge, as well as positive attitudes of respect and tolerance, to appropriately manage dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - VT health personnel must be prepared to carry out continuous ecological stimulation aimed at maintaining the capacities of the individual affected by dementia at a maximum level, delaying the decline of the person affected and to give information about the management and resources in dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Post-graduate Dementia Training Must Health Professionals in General Receive?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - All health and social services professionals must update their knowledge to be competent in the comprehensive management of dementia. Dementia must be addressed in an interdisciplinary fashion, providing care seamlessly from the moment it is detected until the end of life.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Post-graduate Dementia Training Must Health Professionals Engaged in the Specific Care of People with Dementia Receive?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt;- All health and social services professionals integrated into the specialised care of people with dementia must receive specific training that will cover aspects related to the diagnosis and treatment, needs and resources available, ethical and legal aspects, and the need for it to be managed in an interdisciplinary manner.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;How Important Is Research in the Field of Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - The collaboration of everyone involved (health and social services professionals, patients and relatives) is important to make a joint effort in the study and research in dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - Research in dementia must be promoted and fostered from the public administrations, the governing bodies of the State and of the autonomous communities; it must be coordinated with other countries and it must favour the exchange of knowledge between the different teams that work in the same research line in dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;What Role Must the Different Healthcare Levels Play in Research on Dementia?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good clinical practice&lt;/strong&gt; - It is recommendable for the three healthcare levels: PCT, SDCT and the social-health network to participate in research on dementia; to this end, training in research methodology is required.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Scottish Intercollegiate Guidelines Network (SIGN) Levels of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Levels of Evidence: Scottish Intercollegiate Guidelines Network (SIGN)&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th width=&quot;5%&quot; class=&quot;Center&quot; valign=&quot;top&quot;&gt;1++&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High quality meta-analyses, systematic reviews of clinical trials or high-quality clinical trials with very little risk of bias.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1+&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well-conducted meta-analyses, systematic reviews of clinical trials, or well-conducted clinical trials with low risk of bias.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1-&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Meta-analyses, systematic reviews of clinical trials or clinical trials with high risk of bias.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2++&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High-quality systematic reviews of case-control or cohort studies. Cohort or case-control studies with very low risk of bias and with high probability of establishing a causal relationship.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2+&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well-conducted case-control or cohort studies with low risk of bias and a moderate probability of establishing a causal relationship.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;2-&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case-control or cohort studies with a high risk of bias and a significant risk that the relationship is not causal.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Non-analytical studies such as case reports and case series.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;4&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert opinion.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Studies classified as 1- and 2- should not be used in the process of developing recommendations due to their high potential for bias.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Scottish Intercollegiate Guidelines Network (SIGN) Grades of Recommendation for Intervention Studies&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Grades of Recommendation for Intervention Studies: Scottish Intercollegiate Guidelines Network (SIGN)&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least one meta-analysis, systematic review or clinical trial rated as 1++ and directly applicable to the target population of the guideline, or body of scientific evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A body of scientific evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 1++ or 1 +.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A body of scientific evidence consisting of studies rated as 2+, directly applicable to the target population of the guideline and overall consistency of results; or evidence extrapolated from studies classified as 2++.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Scientific evidence level 3 or 4, or extrapolated evidence from studies rated as 2 +.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Good Clinical Practice (GCP)*&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommended practice based on clinical experience and the consensus of the editorial team.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*At times, the development group realised that there were some important practical aspects that they wished to stress but for which there was probably no scientific evidence to support them. In general these cases have to do with some aspects of the treatment considered as good clinical practice and that nobody would normally question. These aspects are evaluated as good practice points. These messages are not an alternative to the scientific evidence-based recommendations, but rather, they must only be considered when there is no other way to highlight this aspect.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grades of Recommendation for Diagnostic Studies&amp;dagger;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; Level of evidence Ia or Ib studies [in the guideline it appears as 2++]&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; Level of evidence II studies [in the guideline it appears as 2+]&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; Level of evidence III studies [in the guideline it appears as 2-]&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; Level of evidence IV studies [in the guideline it appears as 3 or 4]&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&amp;dagger;Adapted from The Oxford Centre for Evidence-based Medicine Levels of Evidence&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate management of patients with Alzheimer's disease and other dementias&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;According to several studies, the most common adverse effects of acetylcholinesterase (ACE) inhibitors are gastrointestinal (nausea, vomiting, diarrhea), and other less frequent ones are anorexia, weight loss, sleep disorders, muscle cramps, urinary incontinence, bradycardia and syncope. The adverse effects are usually mild, transient and dose-dependent. They must be used with caution in the case of renal or hepatic insufficiency. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The main side effects of memantine are: nausea (2.8%), vomiting (3%), dizziness (6.9%), confusion (7.9%), fatigue (2.3%), headache and hallucinations. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The most serious adverse effects in studies of ACE inhibitors in patients with vascular dementia (VD) were syncopes, bradycardia and the possibility of a stroke. Deaths attributed to donepezil in patients with VD are rare and controversial. Bearing in mind that patients with VD usually have a high cardiovascular risk, the possibility of the ACE inhibitors being able to cause potentially serious effects requires caution in their use and stepping up surveillance in their management. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Bear in mind the special sensitivity of patients with behavioural and psychological symptoms of dementia (BPSD) to adverse effects, especially the risk of anticholinergic effects, orthostatic hypotension, falls, extrapyramidal effects, worsening of cognitive function, confusion and delirium. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The risk of adverse effects in the use of psychotropic drugs to treat BPSD is high. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The use of antipsychotics is associated with the following adverse effects: increase in mortality, stroke, sedation, confusion, drowsiness, parkinsonism, dystonia, tardive dyskinesia, akathisia, malignant neuroleptic syndrome, hyperlipidemia, hyperglycaemia, weight increase, orthostatic hypotension, arrhythmias, electrocardiogram (ECG) alterations, anticholinergic effects and cognition worsening. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In one article, the most frequent adverse effects with atypical antipsychotics (aripiprazole, olanzapine, quetiapine or risperidone) compared with placebo were drowsiness (OR = 2.84) and urinary infections (OR = 1.28). Extrapyramidal symptoms (OR = 1.51), movement disorders (OR = 3.42) and peripheral oedema (OR = 1.99) were the most frequent with risperidone and olanzapine. A relevant increase of lesions, falls or syncope was not detected. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The adverse effects most associated with death in risperidone were pneumonia, cardiac insufficiency, cardiac arrest and cerebrovascular disease. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The adverse effects of the benzodiazepines include sedation, worsening of cognition, confusion, delirium, worsening of the memory, paradoxical disinhibition, increase in the risk of falls, worsening of respiratory disorders, tolerance and dependence. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The selective serotonin reuptake inhibitors (SSRIs) produce less anticholinergic effects than classical antidepressants, although they may produce other limiting adverse effects (gastrointestinal, weight loss, sleep alterations, hyponatraemia). They have been associated with falls and fractures due to a different action mechanism to that of the tricyclics. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;False positive and false negative results of diagnostic tests &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Refer to the &quot;Major Recommendations&quot; field and the original guideline document for adverse events associated with pharmacological treatment of specific types of dementia.&lt;/p&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Antipsychotics are contraindicated in Lewy body dementia (DLB) due to the high risk of adverse effects. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Acetylcholinesterase (ACE) inhibitors are contraindicated in patients with epilepsy, asthma or chronic obstructive lung disease, arrhythmias, (with the exception of auricular fibrillation), past history of syncopes, third-degree atrioventricular blocks, sinus node disease, low blood pressure, presence of bradycardia or long QT, active peptic ulcer and urinary retention. They must be used with caution in the case of renal or hepatic insufficiency. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There are no absolute contraindications for memantine use, but it must be used with caution in cases of epilepsy, renal insufficiency or urinary retention. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sleep apnoea is a relative contraindication for the use of benzodiazepines. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Anticholinergics are contraindicated in patients with cardiovascular diseases, prostatism or urinary bladder diseases. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The contraindications of mechanical restraints must be respected and it must not be carried out if not explicitly indicated by the health professional responsible, or if, on the contrary, there are medical orders not to apply it. It must not be used, either, if there are equally effective alternative measures or procedures that have not been tried. They must never be used as punishment or as a show of force, or as a substitute for surveillance, or for the exclusive convenience or comfort of the professionals caring for them. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;This clinical practice guideline (CPG) is a healthcare decision aid. It is not mandatory and it is not a substitute for the clinical judgement of healthcare personnel. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;As in any CPG, however good the methodology used in its preparation, its use must not prevail over the responsibility of the professionals when taking the decisions that adapt best to patients' circumstances, always respecting their opinions, values and beliefs, and always or, whenever possible, consulting their legal representatives. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Dissemination and Implementation Strategy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For this clinical practice guideline (CPG) to reach the health professionals of the Spanish National Health Service (SNS), it will be disseminated through the Gu&amp;iacute;aSalud Catalogue (&lt;a href=&quot;http://www.guiasalud.es&quot; title=&quot;GuiaSalud Web site&quot;&gt;www.guiasalud.es&lt;/a&gt;), also on the Ag&amp;egrave;ncia d'Informaci&amp;oacute;, Avaluaci&amp;oacute; i Qualitat en Salut (AIAQS) website (&lt;a href=&quot;http://www.aatrm.net&quot; title=&quot;AATRM Web site&quot;&gt;www.aatrm.net&lt;/a&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Once the national dissemination plan has ended within the general framework of Gu&amp;iacute;aSalud, the guideline development group, together with the AIAQS, will perform those diffusion activities they consider appropriate.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Measuring the adherence or implementation of the CPG recommendations by monitoring and/or audit can improve its use. The AGREE instrument manual stresses the importance of preparing indicators; item 21 on the applicability dimension deals with this aspect. Consequently, a CPG must offer a list of clear and quantifiable quality indicators or criteria, which are derived from the key recommendations included in the guideline. The most well-known classification of indicators, and used in this guideline is the Donabedian classification, which groups them into: structure, process and results. To know and evaluate compliance with the recommendations considered to be most important, the assessment of some process variables and most important clinical results is proposed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Audit Criteria/Indicators" /><FieldValue Value="Foreign Language Translations" /><FieldValue Value="Mobile Device Resources" /><FieldValue Value="Patient Resources" /><FieldValue Value="Quick Reference Guides/Physician Guides" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="End of Life Care" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Development Group of the Clinical Practice Guideline [trunc]. Clinical practice guideline on the comprehensive care of people with Alzheimer's &#xD;&#xA;disease and other dementias. Barcelona (Spain): Agency for Health Quality and Assessment of Catalonia (AQuAS); 2010. 499 p.  [688 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2010" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Agency for Health Quality and Assessment of Catalonia - State/Local Government Agency [Non-U.S.]" /><FieldValue Value="GuiaSalud - National Government Agency [Non-U.S.]" /><FieldValue Value="Ministry of Health (Spain) - National Government Agency [Non-U.S.]" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This CPG has been funded through the agreement signed by the Instituto de Salud Carlos II, an independent body of the Ministry of Science and Innovation, and the Agencia d'Informaci&amp;oacute;, Avaluaci&amp;oacute; I Qualitat en Salut (AIAQS, previously the Ag&amp;egrave;ncia d'Avaluaci&amp;oacute; de Tecnologia i Recerca M&amp;egrave;diques, AATRM) of Catalonia, within the collaboration framework provided for in the Quality Plan for the National Health System of the Ministry of Health, Social Policy and Equality.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The guideline is editorially independent from the financing entity.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Clinical Practice Guideline (CPG) Development Group on the Comprehensive Care of People with Alzheimer's Disease and Other Dementias&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Development Group Members&lt;/em&gt;: Maria Teresa Abell&amp;aacute;n Vidal, neurologist, Centres Assistencials Emili Mira, Institute of Neuropsychiatry and Addictions, Parc de Salut Mar (Barcelona); Luis Ag&amp;uuml;era Ortiz, psychiatrist, Hospital Universitario 12 de Octubre (Madrid); Miquel Aguilar Barber&amp;aacute;, neurologist, Hospital Universitario Mutua of Terrassa (Barcelona); Daniel Andr&amp;eacute;s Alcolea Rodr&amp;iacute;guez, neurologist, Hospital de la Santa Creu i Sant Pau (Barcelona); Consol Almenar Monfort, neurologist, Hospital Benito Menni, Sant Boi de Llobregat (Barcelona); Guillermo Amer Ferrer, neurologist, Hospital Universitario Son Dureta (Mallorca), Pilar de Azpiazu Artigas, psychogeriatrician, Hospital Benito Menni, Sant Boi de Llobregat (Barcelona); Dolors Badenes Gu&amp;iacute;a, neuropsychologist, Hospital Universitario Mutua of Terrassa (Barcelona); Jos&amp;eacute; Miguel Baena D&amp;iacute;az, general practitioner, La Marina Primary Care Centre (Barcelona); F&amp;eacute;lix Bermejo Pareja, neurologist, Hospital Universitario 12 de Octubre (Madrid); Marcelo Berthier Torres, neurologist, Medical-Health Research Centre,&amp;nbsp;University of Malaga (Malaga); &amp;Iacute;ngrid Bullich Mar&amp;iacute;n, nurse, Pla Director Sociosanitari, Departament de Salut, Generalitat de Catalunya; Carmen Caja L&amp;oacute;pez, nurse, director of the Pla Director Sociosanitari,&amp;nbsp;Departament de Salut, Generalitat de Catalunya; Noem&amp;iacute; Calzado Mart&amp;iacute;nez, psychologist, Hospital Universitario Mutua de Terrassa (Barcelona); Jaume Campdelacreu Fumad&amp;oacute;, neurologist, Hospital Universitario de Bellvitge (Barcelona); M.&amp;ordf; Pilar Ca&amp;ntilde;abate Gonz&amp;aacute;lez, social worker, Fundaci&amp;oacute; ACE, Institut Catal&amp;agrave; de Neuroci&amp;egrave;ncies Aplicades (Barcelona); Montserrat Coma Sol&amp;eacute;, general practitioner, Les Planes Primary Health Centre, Sant Joan Desp&amp;iacute; (Barcelona); Josep Llu&amp;iacute;s Conde Sala, psychologist, University of Barcelona; Maria-Dolors Estrada Sabadell, public health and preventivist physician, Ag&amp;egrave;ncia d'Informaci&amp;oacute;, Avaluaci&amp;oacute; i Qualitat en Salut (AIAQS) (Barcelona); Inmaculada Fern&amp;aacute;ndez Verde, pharmacist, president of the Federaci&amp;oacute; d'Associacions de Familiars d'Alzheimer de Catalunya; Carme Ferrando Belart, psychologist, Pla Director Sociosanitari. Departament de Salut, Generalitat de Catalunya; Isidre Ferrer Abizanda, neuropathologist, Universidad de Barcelona, Hospital Universitario de Bellvitge (Barcelona); Esther Flores Mart&amp;iacute;n, nurse, Hospital Sant Andreu, Fundaci&amp;oacute;n Sociosanitaria de Manresa (Barcelona); Benito J. Fontecha G&amp;oacute;mez, geriatrician, Consorci Sanitari Integral, Hospitalet de Llobregat (Barcelona); Francesc Formiga P&amp;eacute;rez, geriatrician, Hospital Universitario de Bellvitge (Barcelona); Isabel Fort Almi&amp;ntilde;ana, geriatrician, Centre Sociosanitari El Carme, Badalona (Barcelona); Ana Frank Garc&amp;iacute;a, neurologist, Hospital Universitario La Paz (Madrid); Roc&amp;iacute;o Garc&amp;iacute;a Cobos, neurologist, Hospital Universitario La Paz (Madrid); Guillermo Garc&amp;iacute;a Ribas, neurologist, Hospital Ram&amp;oacute;n y Cajal (Madrid); Jordi Gasc&amp;oacute;n Bayarri, neurologist, Hospital Universitario de Bellvitge (Barcelona); Olga Gelonch Rosinach, neuropsychologist, Associaci&amp;oacute; de Parapl&amp;egrave;gics i Discapacitats, F&amp;iacute;sics de Lleida (ASPID) (Lleida); M.&amp;ordf; Rosa Giner Qui&amp;ntilde;onero, president of the Associaci&amp;oacute; de Familiars d'Alzheimer del Baix Llobregat (Barcelona); Xavier G&amp;oacute;mez-Batiste, oncologist, director of the Collaboration Centre of the World Health Organisation (WHO) for Public Palliative Care Programmes, Hospitalet de Llobregat (Barcelona); Antonia Gonz&amp;aacute;lez Castilla, post-graduate student in dementia and Alzheimer, Associaci&amp;oacute; de Familiars d'Alzheimer del Baix Llobregat (Barcelona); M.&amp;ordf; Jes&amp;uacute;s Gonz&amp;aacute;lez Moneo, general practitioner, San Mart&amp;iacute;n Primary Care Centre (Barcelona); Jaime Kulisevsky Bojarski, neurologist, Hospital de la Santa Creu i Sant Pau (Barcelona); Albert Lle&amp;oacute; Bisa, neurologist, Hospital de la Santa Creu i Sant Pau (Barcelona); M.&amp;ordf; Dolores Mart&amp;iacute;nez Lozano, neurologist, Hospital La Magdalena (Castellon); M.&amp;ordf; Jes&amp;uacute;s Megido Badia, nurse, Centro Health Centre, Hospitalet de Llobregat (Barcelona); Jos&amp;eacute; L. Molinuevo Guix, neurologist, Hospital Cl&amp;iacute;nic i Provincial de Barcelona (Barcelona); Ana Morera Bay&amp;oacute;, neuropsychologist, Associaci&amp;oacute; Vall&amp;egrave;s Amics de la Neurologia (Barcelona); &amp;Aacute;ngel Mori&amp;ntilde;igo Dom&amp;iacute;nguez, psychiatrist, Psychiatry Studio (Seville); Marta Obdulia G&amp;oacute;mez, business management and administration, Associaci&amp;oacute; Vall&amp;egrave;s Amics de la Neurologia (Barcelona); Javier Pagonabarraga Mora, neurologist, Hospital de la Santa Creu i Sant Pau, (Barcelona); Pau Pastor Mu&amp;ntilde;oz, neurologist and specialist in genetics, Cl&amp;iacute;nica Universitaria de Navarra;and CIMA (Pamplona); Jordi Pe&amp;ntilde;a Casanova, neurologist, Parc de Salut Mar (Barcelona); Cristina Pi&amp;ntilde;ol Uson, nurse, High Dependence Complexity Unit, Institut Catal&amp;agrave; de la Salut (Tarragona); Luis M. Planchat Teruel, forensic medical examiner and psychologist, Instituto de Medicina Legal de Catalunya (Barcelona); Francesc Pujadas Navin&amp;eacute;s, neurologist, Hospital Universitario Vall d'Hebron (Barcelona); Joaquim Pujol Dom&amp;egrave;nech, psychiatrist and neurologist (Barcelona); Pilar Quilez Ferrer, neurologist, Hospital Universitario Mutua de Terrassa (Barcelona); Ramon Re&amp;ntilde;&amp;eacute; Ram&amp;iacute;rez, neurologist, Hospital Universitario de Bellvitge (Barcelona); Sebasti&amp;agrave; Riu Subirana, general practitioner, SRET i Respir de Llars Mundet, Diputaci&amp;oacute; de Barcelona (Barcelona); Alfredo Robles Bay&amp;oacute;n, neurologist, Cognitive Neurology Unit of the Hospital Policl&amp;iacute;nico La Rosaleda. Santiago de Compostela (Pontevedra); Montserrat Rod&amp;oacute; Cobo, nurse, Pla Director Sociosanitari. Departament de Salut, Generalitat de Catalunya; Rosa M.&amp;ordf; Rodr&amp;iacute;guez Fern&amp;aacute;ndez, neurologist, Complejo Hospitalario de Ourense (Ourense); Marcel Rosich Estrag&amp;oacute;, neurologist, Institut Pere Mata, Reus (Tarragona); Anna Rovira Cair&amp;oacute;, lawyer, Pinyol Advocats, SLP, Alzheimer Catalunya Fundaci&amp;oacute; Privada (Barcelona); Pedro Roy Mill&amp;aacute;n, psychiatrist, Hospital Mare de D&amp;eacute;u de la Merc&amp;egrave; (Barcelona); Jes&amp;uacute;s Ruiz Idiago, psychiatrist, Hospital Mare de D&amp;eacute;u de la Merc&amp;egrave; (Barcelona); Raquel S&amp;aacute;nchez del Valle D&amp;iacute;az, neurologist, Hospital Cl&amp;iacute;nic i Provincial de Barcelona (Barcelona); Joan Santamaria Cano, neurologist, Hospital Cl&amp;iacute;nic i Provincial de Barcelona (Barcelona); N&amp;uacute;ria Terribas Sala, lawyer and director of the Institut Borja de Bio&amp;egrave;tica, Esplugues de Llobregat (Barcelona); Gemma Tom&amp;eacute; Corruesco, social worker, Hospital Universitario Mutua de Terrassa (Barcelona); Antoni Turon Estrada, neurologist, Hospital Santa Caterina, Salt (Girona); Eduard Vinyamata Camp, sociologist, Universitat Oberta de Catalunya (Barcelona); Rosa M.&amp;ordf; Y&amp;aacute;&amp;ntilde;ez Ba&amp;ntilde;a, neurologist, Complejo Hospitalario de Ourense (Ourense)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Coordination&lt;/em&gt;: Carmen Caja L&amp;oacute;pez, nurse, director Pla Director Sociosanitari, Departament de Salut, Generalitat de Catalunya &lt;em&gt;(General Coordinator&lt;/em&gt;); Miquel Aguilar Barber&amp;aacute;, neurologist, Hospital Universitario Mutua of Terrassa (Barcelona) (&lt;em&gt;General Clinical Coordinator&lt;/em&gt;); Ramon Re&amp;ntilde;&amp;eacute; Ram&amp;iacute;rez, neurologist, Hospital Universitario of Bellvitge (Barcelona) (&lt;em&gt;General Clinical Coordinator&lt;/em&gt;); Jaume Campdelacreu Fumad&amp;oacute;, neurologist, Hospital Universitario of Bellvitge (Barcelona) (&lt;em&gt;Subgroup Clinical Collaborator&lt;/em&gt;); Pilar Quilez Ferrer, neurologist, Hospital Universitario Mutua of Terrassa (Barcelona) (&lt;em&gt;Subgroup Clinical Collaborator&lt;/em&gt;); Raquel S&amp;aacute;nchez del Valle D&amp;iacute;az, neurologist, Hospital Cl&amp;iacute;nic i Provincial of Barcelona (Barcelona) (&lt;em&gt;Subgroup Clinical Collaborator&lt;/em&gt;); Maria-Dolors Estrada Sabadell, Preventive physician and Public Health, AIAQS (Barcelona) (&lt;em&gt;Technical Coordination and Methodology Advice&lt;/em&gt;); Carme Ferrando Belart, technical support Pla Director Sociosanitari, Departament de Salut, Generalitat de Catalunya (&lt;em&gt;Technical Secretariat&lt;/em&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Collaboration&lt;/em&gt;: Mireia Espallargues Carreras, Preventive physician and Public Health, AIAQS (Barcelona); Marta Millaret Senpau, documentation support technician, AIAQS (Barcelona); Toni Parada Mart&amp;iacute;nez, documentalist, AIAQS (Barcelona)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;External Review&lt;/em&gt;: Rafael Blesa Gonz&amp;aacute;lez, neurologist, Hospital de la Santa Creu i Sant Pau (Barcelona); Merc&amp;egrave; Boada Rovira, neurologist, Fundaci&amp;oacute; ACE, Institut Catal&amp;agrave; de Neuroci&amp;egrave;ncies Aplicades, Hospital Universitari Vall d'Hebron-Institut de Recerca, Universitat Aut&amp;ograve;noma of Barcelona (VHIR-UAB) (Barcelona); Luis Ignacio Brusco, psychiatrist, Faculty of Medicine, Buenos Aires (Argentina); Manuel A. Franco Mart&amp;iacute;n, psychiatrist, Healthcare Complex of Zamora (Zamora)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All the members of the development group as well as the people who have participated as collaborators and external reviewers (either individually or as representatives of entities) have made the declaration of conflict of interests reflected in Appendix 5 in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in &lt;a href=&quot;http://www.guiasalud.es/GPC/GPC_484_Alzheimer_AIAQS_comp_eng.pdf&quot; title=&quot;GuiaSalud Web site&quot;&gt;English&lt;/a&gt; and &lt;a href=&quot;http://www.guiasalud.es/egpc/alzheimer/completa/index.html&quot; title=&quot;GuiaSalud Web site&quot;&gt;Spanish&lt;/a&gt; from the Gu&amp;iacute;aSalud Web site.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Quick reference guides are available in a variety of dialects from the &lt;a href=&quot;http://portal.guiasalud.es/web/guest/catalogo-gpc?p_p_id=EXT_16&amp;amp;p_p_lifecycle=0&amp;amp;p_p_state=pop_up&amp;amp;p_p_mode=view&amp;amp;p_p_col_id=column-3&amp;amp;p_p_col_pos=1&amp;amp;p_p_col_count=4&amp;amp;_EXT_16_struts_action=/ext/catalogo/vista_previa&amp;amp;_EXT_16_contenidoId=73805&amp;amp;_EXT_16_version=2.2&amp;amp;_EXT_16_languageId=en_UK&amp;amp;_EXT_16_OtraVentana=si&quot; title=&quot;GuiaSalud Web site&quot;&gt;Gu&amp;iacute;aSalud Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A summary version is available in Spanish from the &lt;a href=&quot;http://www.guiasalud.es/GPC/GPC_484_Alzheimer_AIAQS_resum.pdf&quot; title=&quot;GuiaSalud Web site&quot;&gt;Gu&amp;iacute;aSalud Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Methodology manual for developing clinical practice guidelines of the Spanish National Healthcare System. Available in Spanish from the &lt;a href=&quot;http://portal.guiasalud.es/emanuales/elaboracion/index-02.html&quot; title=&quot;GuiaSalud Web site&quot;&gt;Gu&amp;iacute;aSalud Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;In addition, diagnostic criteria for Alzheimer's disease and other dementias are provided in Appendix 1 and implementation indicators are provided in Section 16 of the &lt;a href=&quot;http://www.guiasalud.es/GPC/GPC_484_Alzheimer_AIAQS_comp_eng.pdf&quot; title=&quot;GuiaSalud Web site&quot;&gt;original guideline document&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Spanish version of the guideline is available via a mobile application from the &lt;a href=&quot;http://portal.guiasalud.es/web/guest/english-cpg&quot; title=&quot;GuiaSalud Web site&quot;&gt;Gu&amp;iacute;aSalud Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patient information is available in English in Appendix 2 of the &lt;a href=&quot;http://www.guiasalud.es/GPC/GPC_484_Alzheimer_AIAQS_comp_eng.pdf&quot; title=&quot;GuiaSalud Web site&quot;&gt;original guideline document&lt;/a&gt; and in Spanish from the &lt;a href=&quot;http://www.guiasalud.es/egpc/alzheimer/pacientes/01_que_es_demencia.html&quot; title=&quot;GuiaSalud Web site&quot;&gt;Gu&amp;iacute;aSalud Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on June 25, 2014. The information was verified by the guideline developer on August 1, 2014.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
